US20070141076A1 - Antigen fragments for the diagnosis of Toxoplasma gondii - Google Patents
Antigen fragments for the diagnosis of Toxoplasma gondii Download PDFInfo
- Publication number
- US20070141076A1 US20070141076A1 US11/586,694 US58669406A US2007141076A1 US 20070141076 A1 US20070141076 A1 US 20070141076A1 US 58669406 A US58669406 A US 58669406A US 2007141076 A1 US2007141076 A1 US 2007141076A1
- Authority
- US
- United States
- Prior art keywords
- seq
- antigen
- fragments
- toxoplasma gondii
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 117
- 239000000427 antigen Substances 0.000 title claims abstract description 98
- 108091007433 antigens Proteins 0.000 title claims abstract description 98
- 102000036639 antigens Human genes 0.000 title claims abstract description 98
- 241000223997 Toxoplasma gondii Species 0.000 title claims abstract description 45
- 238000003745 diagnosis Methods 0.000 title claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 69
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 40
- 208000015181 infectious disease Diseases 0.000 claims abstract description 29
- 239000013598 vector Substances 0.000 claims abstract description 22
- 244000045947 parasite Species 0.000 claims abstract description 18
- 238000002823 phage display Methods 0.000 claims abstract description 10
- 108020004414 DNA Proteins 0.000 claims description 36
- 239000002299 complementary DNA Substances 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 29
- 201000005485 Toxoplasmosis Diseases 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 15
- 239000003446 ligand Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 238000009396 hybridization Methods 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000009257 reactivity Effects 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 108091034117 Oligonucleotide Proteins 0.000 description 21
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 15
- 230000000903 blocking effect Effects 0.000 description 15
- 238000003314 affinity selection Methods 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 13
- 230000004927 fusion Effects 0.000 description 13
- 229940027941 immunoglobulin g Drugs 0.000 description 13
- 238000011534 incubation Methods 0.000 description 12
- 238000010369 molecular cloning Methods 0.000 description 12
- 241001515965 unidentified phage Species 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037865 fusion proteins Human genes 0.000 description 10
- 230000008348 humoral response Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 210000000059 tachyzoite Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101100056797 Canis lupus familiaris SAG gene Proteins 0.000 description 4
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101150073248 GRA2 gene Proteins 0.000 description 4
- 101100532512 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAG1 gene Proteins 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035935 pregnancy Effects 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 108010020567 12E7 Antigen Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 210000000061 bradyzoite Anatomy 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012909 foetal bovine serum Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000008482 12E7 Antigen Human genes 0.000 description 2
- 101100355577 Arabidopsis thaliana ARAC11 gene Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 101150010973 GRA1 gene Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 101100122821 Toxoplasma gondii GRA3 gene Proteins 0.000 description 2
- 101100069385 Toxoplasma gondii GRA6 gene Proteins 0.000 description 2
- 101100069387 Toxoplasma gondii GRA7 gene Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 101150078331 ama-1 gene Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 108010045673 endodeoxyribonuclease XBAI Proteins 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000007852 inverse PCR Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003250 oocyst Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 101710122462 65 kDa protein Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101100162403 Arabidopsis thaliana ALEU gene Proteins 0.000 description 1
- 101100523500 Arabidopsis thaliana ARAC4 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 208000018478 Foetal disease Diseases 0.000 description 1
- 241000272496 Galliformes Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000740062 Homo sapiens BAG family molecular chaperone regulator 1 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000904259 Homo sapiens Glycerol-3-phosphate acyltransferase 3 Proteins 0.000 description 1
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 description 1
- 101150114220 MIC4 gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100022239 Peroxiredoxin-6 Human genes 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710188053 Protein D Proteins 0.000 description 1
- 101710132893 Resolvase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 101100069381 Toxoplasma gondii GRA4 gene Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000001938 anti-toxoplasmal effect Effects 0.000 description 1
- GHPGOEFPKIHBNM-UHFFFAOYSA-N antimony(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Sb+3].[Sb+3] GHPGOEFPKIHBNM-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 108010021310 endodeoxyribonuclease NcoI Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000007519 figuring Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000014639 sexual reproduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/45—Toxoplasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the invention described herein relates to a method for identifying antigen fragments of Toxoplasma gondii proteins, and their use as diagnostic and immunogenic agents. Said method is implemented by means of selection of cDNA libraries of the parasite or of DNA fragments of specific genes of the parasite with sera of subjects who have been infected by the parasite, using the phage display technique, and is characterised in that it uses the vector ⁇ KM4.
- the invention described herein also relates to the technical field of the preparation of diagnostic means not applied directly to the animal or human body and furnishes compounds, methods for their preparation, methods for their use and compositions containing them which are suitable for industrial application in the pharmaceutical and diagnostic field, particularly for the detection and diagnosis of Toxoplasma gondii infections, as well as for the treatment and prevention of said infections.
- early diagnosis is a priority and highly desirable objective in all fields of medicament, particularly because it allows an appreciable improvement in the patient's life and a concomitant saving on the part of health care systems or on the part of the actual patients.
- early diagnosis is that of potential or existing Toxoplasma gondii infection in pregnant women, with particular concern for the health of the foetus, and in infected subjects, particularly those with impaired immunity.
- Toxoplasma gondii is an obligate intracellular parasite that infects all mammalian cells, including those of human subjects (McCabe and Remington, N. Engl. J. Med. 1988, 318-313-5), and other animal genera, e.g. birds.
- the life cycle of the parasite is complex and one may distinguish between three stages of infection: tachyzoite (asexual), bradyzoite (in tissue cysts, asexual) and sporozoite (in oocysts, sexual reproduction). Transmission typically occurs through ingestion of undercooked meat harbouring tissue cysts or vegetables contaminated with oocysts shed by cats. Human infection is generally asymptomatic and self-limiting in immunocompetent hosts.
- toxoplasmosis is a severe opportunist infection, which may give rise to encephalitis with very serious outcomes (Luft, B. J., Remington J. S., 1992, Clin. Infect. Dis. 15, 211-22).
- contracting primary infection during pregnancy may lead to miscarriages or to severe foetal disease in mammals.
- T. gondii infection Diagnosis of T. gondii infection is established by isolating the micro-organism in the blood or body fluids, identifying the parasite in tissues, detecting specific nucleotide sequences with PCR, or by detecting specific anti- T. gondii immunoglobulins produced by the host in response to the infection (Beaman et al., 1995 Principles and Practice of Infectious Diseases 4th Ed., Churchill Livingstone Inc., New York, 2455-75; Remington J S et al. 1995, Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders, Philadelphia, Pa., 140-267).
- T. gondii antigens have long been known and available, first of all as antigen mixtures obtained in various ways (FR 2,226,468, Meriéux; SU 533376, Veterinary Research Institute; JP 54044016, Nihon Toketsu Kanso), then as subsequent isolations of pure antigens (EP 0 082 745, Merieux; EP 0 301 961, INSERM, Pasteur; WO 89/5658, Transgene) and their characterisation both as proteins, and of their respective genes (WO 89/08700, U. Leland, Dartmouth Coll.; U.S. Pat. No. 4,877,726, Res. Inst.
- GRA1 or P24
- GRA2 or P28
- GRA4 WO 93/25689, INSERM, Pasteur; U.S. Pat. No. 5,633,139, U.S. Pat. No. 5,665,542, U.S. Pat. No. 5,686,575, Res. Inst. Palo Alto; Prince et al., Mol. Biochem. Parasitol., 34 3-14
- GRA4 Mevelec et al., Mol.
- the antigens were obtained with well-known recombinant cDNA techniques in expression vectors.
- WO 98/08700 uses known expression vectors in phage ⁇ gt11.
- WO 98/12683 uses the same phage and transfects E. coli with a proprietary plasmid, or by preparing a special expression cassette, as in WO 96/02654.
- EP 0 724 016 obtains mimotypes, using combinatorial expression libraries of peptides.
- EP 0 301 961 describes how to obtain excretion-secretion antigens with molecular weights ranging from 20 kDa to 185 kDa.
- WO 89/05658 describes a protein containing the epitopes of the 24 kDa protein recognised by the antibodies produced against Toxoplasma excretion-secretion antigens; this protein is obtained by transfection of cells by means of expression vectors.
- the antigen P28 (GRA2) is described in U.S. Pat. No. 5,633,139 and the method of obtaining it is again implemented through expression in phage ⁇ gt11.
- the antigen P32 (GRA6) is described in patent FR 2,702,491, the antigen ROP1 (P66) in U.S. Pat. No. 5,976,553, P35 (or GRA8) in EP 0 431 541, WO 99/57295 and WO 99/61906, and lastly P68 in EP 0 431 541.
- the invention described herein uses a new vector of DNA expression and protein exposure as molecular fusion with the amino-terminal part of protein D of the lambda bacteriophage capsid (pD) ( ⁇ KM4).
- the expression/exposure vector was described for the first time in patent application PCT/IT01/00405, filed on Jul. 26, 2001, the most important part of which is incorporated herein.
- This vector called ⁇ KM4, differs from that used in expression only experiments ( ⁇ gt11) in that the recombinant protein coded for by the DNA fragment is expressed as fusion with a protein of the bacteriophage itself and then exposed on the capsid.
- the phage exposes the protein fragment on the surface only if its open reading frame (ORF) coincides with pD.
- the size of the fragments of DNA cloned in our libraries was selected in order to represent a population of medium size ranging from 300 to 1000 nucleotide base pairs (bp), and, for statistical reasons, most of the out-of-frame sequences contain stop codons which do not permit their translation and consequently exposure on the surface of the phage.
- one object of the invention described herein is a method for the identification of antigen fragments of Toxoplasma gondii proteins, by means of the selection of libraries of DNA fragments with sera of subjects who have been infected by the parasite, using the phage display technique, characterised in that it uses the vector ⁇ KM4.
- Another object of the present invention are antigen fragments obtainable with the above-mentioned method, both isolated and characterised, and as sets of antigen fragments called “collections”.
- the invention described herein also extends to the antigen portions of said fragments (epitopes).
- antigen fragments as active agents, particularly with an immunogenic action, for the preparation of medicaments for the prevention and therapy of Toxoplasma gondii infection, constitute a further object of the present invention.
- Another object of the present invention are the gene sequences coding for the above-mentioned antigen fragments, their use as medicaments, particularly for the prevention and therapy of Toxoplasma gondii infection, e.g. as gene therapy.
- the present invention also extends to the gene sequences that hybridise with the sequences of the above-mentioned fragments in stringent hybridisation conditions.
- Another object of the present invention are anti-epitope antibodies and their use in the preparation of diagnostic, preventive and therapeutic means, e.g. as conjugates with active ingredients such as chemo-therapy agents.
- Antibodies can be generated also against collections of said epitopes.
- the method provided by the present invention makes it possible to confirm the use of the Toxoplasma gondii antigens described above as such as diagnostic agents and also to identify in known antigens the epitopes that trigger an immune response in human subjects; this portion is a further object of the present invention; but it also makes it possible to identify the antigenic function of proteins of Toxoplasma gondii, or of portions thereof, which, though their structure and possibly their physiological function may be known, are unknown as regards their antigenic function, and such function comes within the framework of the present invention; lastly, the method according to the present invention also provides new antigen fragments of Toxoplasma gondii proteins, that constitute yet another object of the present invention.
- Another object of the present invention is the use of the antigen fragments thus identified for the preparation of means of diagnosing the infection, as well as the actual diagnostic means containing them.
- the use realtes also to the diagnosis of the time of the infection, in particular by the IgG avidity assay.
- Another object of the present invention is the use of the antigen fragments thus identified as medicaments, particularly for the preparation of formulations, and particularly in the form of vaccines, which are useful for the prevention and cure of the infection.
- the vaccines according to the present invention are suitable for use in humans and other animals (particularly pigs, cats, sheeps).
- Another object of the present invention are ligands generated from the above-mentioned antigen fragments and the related collections and the use of such ligands for the preparation of diagnostic means for the detection of the infection, with particular reference to the time of infection, as well as therapeutic means for the prevention and treatment of the infection itself.
- Another object of the present invention is a method for the diagnosis of Toxoplasma gondii infection, comprising the selection of sera of subjects affected or suspected of being affected by said infection with the above mentioned antigen fragments and/or their collection and/or at least one ligand and/or antibody.
- FIG. 1 represents the map of the vector ⁇ KM4.
- the present invention comprises the construction of expression/exposure libraries of DNA fragments prepared from Toxoplasma gondii cells, the selection of such libraries with the sera of patients who have been infected by Toxoplasma gondii, the characterisation of the antigen fragments, and the use of said fragments for developing selective diagnostic means.
- the present invention may entail the generation of specific ligands for said antigen fragments (e.g. human recombinant antibodies or humanised murine recombinant antibodies) and the construction of selective diagnostic means that incorporate the ligands generated.
- specific ligands for said antigen fragments e.g. human recombinant antibodies or humanised murine recombinant antibodies
- Antibodies and ligands of the present invention can be obtained according according to the general common knowledge and conventional methods.
- the method according to the present invention advantageously combines affinity selection and the power of phage display.
- phage display is a strategy based on the selection of expression/exposure libraries in which small protein domains are exposed on the surface of bacteriophages containing the corresponding genetic information.
- messenger RNA was purified from an adequate number of cells (e.g. 10 6 cells), using common commercially available means, from which the corresponding cDNA was generated. The latter was fragmented (by means of the bacterial enzyme DNaseI) and then cloned in the expression/exposure vector ⁇ KM4 (see example).
- each specific T. gondii gene was amplified from the DNA of the parasite (either cDNA or genomic DNA, both prepared by using common commercially available kits) by means of PCR with specific synthetic oligonucleotides. DNA of single genes was then fragmented randomly by means of the bacterial enzyme DNaseI and then cloned as a pool in the expression/exposure vector ⁇ KM4.
- the amplification of the libraries was done by means of normal techniques with which the expert in the field is familiar, e.g. by plating, growth, elution, purification and concentration (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY).
- the libraries were then used to develop the selection conditions, screening and characterisation of the sequences identified.
- the phage clones identified were characterised by immunoenzymatic assays.
- a library of the phage display type constructed using cDNA deriving from cells of pathogenic organisms, makes it possible to exploit affinity selection, which is based on incubation of specific sera (reactive with the pathogen) with collections of bacteriophages that express portions of proteins of the pathogen on their capside and that contain the corresponding genetic information.
- the bacteriophages that specifically bind the antibodies present in the serum are easily recovered, remaining bound (by the antibodies themselves) to a solid support (e.g. magnetic beads); the non-specific ones, by contrast, are washed away.
- Direct screening i.e. the analysis of the ability of single phage clones to bind the antibodies of a given serum, is done only at a later stage, when the complexity of the library (i.e. the different number of sequences) is substantially reduced, precisely as a result of the selection.
- the use of selection strategies allows faster analysis of a large number of different protein sequences for the purposes of identifying those that respond to a particular characteristic, e.g. interacting specifically with antibodies present in the serum of patients who have been infected by the pathogen.
- affinity selection and phage display makes it possible to use a smaller amount of serum for each analysis.
- the direct screening of a classic cDNA library entails the use of large amounts of serum, which are not always easy to obtain. For example, to analyse a library of approximately 10 6 independent clones it would be necessary to incubate along with the preselected serum the numerous filters containing a total of approximately 10 7 phage plaques transferred from the different culture plates with the infected bacteria (e.g. a serum volume of 1-10 ml).
- the use of a display-type library permits affinity selection in small volumes (0.1-1 ml) prior to direct screening, and from limited amounts of serum, such as, for example, 10 ⁇ l.
- a further advantage of the use of display-type libraries consists in analysing a number of independent clones (particles of recombinant phages exposing different cDNA sequences on their surfaces) 10-100 times greater (e.g. 10 8 different bacteriohages) than expression-alone libraries where, as a result of technical problems, not more than 10 6 independent clones are normally analysed.
- one possible realisation of the present invention is in the form of diagnostic kits containing the antigen fragments and/or ligands and/or antibodies described above.
- FIG. 1 presents the map of the vector ⁇ KM4.
- FIG. 1 represents the map of the vector ⁇ KM4.
- the plasmid pNS3785 (Sternberg and Hoess, 1995, Proc. Natl. Acad. Sci.
- the lambda gene pD was amplified with PCR from the plasmid pNS3785 using the primers 5′-CCGCCTT CCATGG GT ACTAGT TTTAAAT GCGGCCGC ACGAGCAAAGAAACCTTTAC-3′ (SEQ ID No 3) e 5′-AGCTT CCTAGG GCTGGGTCTAG-3′ (SEQ ID No 4) containing the restriction sites NcoI, SpeI, NotI and EcoRI, respectively, (underlined).
- the PCR product was then purified, digested with NcoI and EcoRI endonuclease and recloned in sites NcoI and EcoRI of pKM3, resulting in the plasmid pKM4 bearing only the restriction sites SpeI and NotI at the 5′ end of the protein gpD.
- the plasmid was then digested with XbaI endonuclease and cloned in the XbaI site of the lambda phage Dam15imm21nin5 (Sternberg and Hoess, 1995, Proc. Natl. Acad. Sci. USA., 92:1609-1613).
- Tachyzoites of the protozoon Toxoplasma gondii were grown in vitro in monkey kidney cells (“VERO” African green monkey cells) using DMEM culture medium containing 10% foetal bovine serum, 2 mM glutamine and 0.05 mg/ml gentamicin (Gibco BRL, Canada).
- the parasites were collected after complete lysis of the host cells and purified by filtration (filter porosity 3 ⁇ m) followed by centrifuging. 4 ⁇ g of mRNA were isolated from 10 7 tachyzoites using the “QuickPrep Micro mRNA Purification Kit” (Amersham Pharmacia Biotech, Sweden) and following the manufacturer's instructions.
- the double-helix cDNA was synthesised from 200 ng of poly(A) + RNA using the “SMART cDNA Library Construction Kit” (Clontech, CA, USA) and following the manufacturer's instructions. 10 ⁇ g of total cDNA were then fragmented randomly using 0.5 ng of the endonuclease DNaseI (Sigma-Aldrich, USA). The mixture of cDNA and DNaseI was incubated for 20 minutes at 15° C. and the cDNA fragments were purified with extraction in phenol/chloroform and subsequent purification by means of the “QIAquick PCR Purification Kit” (Qiagen, CA, USA), following the manufacturer's instructions.
- the 3 ⁇ g ends of the cDNA fragments were “flattened” by incubating the DNA with 9 units of the enzyme T4 DNA polymerase (New England Biolabs, MA, USA) for 60 minutes at 15° C.
- the fragments were then purified by means of extraction in phenol/chloroform and subsequent precipitation in ethanol. 500 ng of the resulting DNA were bound with a 20-fold molar excess of “synthetic adaptors” for the purposes of adding the restriction sites SpeI and NotI to the ends of the fragments.
- the excess of unligated adaptors was removed from the ligation mixture by electrophoresis on 2% agarose gel and the cDNA fragments with molecular weights ranging from 300 bp to 1000 bp were excised from the gel and purified by means of the “Qiaquick gel extraction kit” (Qiagen, CA, USA) following the manufacturer's instructions.
- the vector ⁇ KM4 was digested with SpeI/NotI and for the construction of the library 6 ligation mixtures were performed, each containing 0.4 ⁇ g of vector and approximately 7 ng of insert. After overnight incubation at 4° C.
- the ligation mixtures were packaged in vitro with the “Ready-To-Go lambda packaging kit” (Amersham Pharmacia Biotech, Sweden) and plated for infection of BB4 cells (bacterial cells of E. coli strain BB4; Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY). After overnight incubation at 37° C. the phage was eluted from the plates with SM buffer (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY), purified, concentrated and stored at ⁇ 80° C. in SM buffer containing 7% dimethylsulphoxide. The complexity of the library calculated as the number of total independent clones with inserts was 10 7 clones.
- the beads were washed 10 times with 1 ml of washing solution (PBS, 1% TritonX100, 10 mM MgSO 4 ).
- the bound bacteriophages were amplified for infection of BB4 cells added directly to the beads (1.2 ml per selection) and subsequent 30-minute incubation at room temperature.
- 12 ml of NZY-Top Agar (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY) were added to the mixture of beads and cells and immediately poured onto NZY plates (2 15-cm Petri capsules for selection). The plates were incubated for 12-16 hours at 37° C.
- phages were collected from the plates by means of the addition of 15 ml of SM buffer per plate and stirring for 4 hours at room temperature.
- the phages were purified by precipitation in PEG/NaCl (20% polyethylene glycol, NaCl 1M) and finally resuspended in 5 ml of SM and stored at +4° C.
- an affinity selection procedure consisting of two “panning” cycles with one or more positive sera (that is to say sera deriving from a patient who tested positive for the presence of antibodies directed against the parasite), followed by an immunological screening procedure carried out with the same sera or, alternatively, by analysis of single clones taken at random from the mixture of selected phages.
- the library was selected with 10 positive sera (T1, T2, T3, T4, T5, T6, T7, T8, T9 and T10), generating, after a single selection cycle, the corresponding mixtures p1 I , p2 I , p3 I , p4 I , p5 I , p6 I , p7 I , p8 I , p9 I and p10 I .
- Multi-well plates (Immunoplate Maxisorb, Nunc, Denmark) were coated, incubating 100 ⁇ l/well of anti-lambda polyclonal antibodies overnight at 4° C. with a concentration of 0.7 ⁇ g/ml in NaHCO 3 50 mM, pH 9.6. After eliminating the coating solution, the plates were incubated with 250 ⁇ l of blocking solution (5% skimmed milk powder in PBS, 0.05% Tween-20). The plates were then washed twice with washing buffer (PBS, 0.05% Tween-20). A mixture of 100 ⁇ l of blocking solution containing phage lysate (diluted 1:1) was added to each well and incubated for 60 minutes at 37° C.
- blocking solution 5% skimmed milk powder in PBS, 0.05% Tween-20
- 1 ⁇ l of human serum was preincubated for 30 minutes at room temperature with 10 9 wild-type phage particles, 1 ⁇ l of rabbit serum, 1 ⁇ l of bacterial extract of BB4 cells, 1 ⁇ l of foetal bovine serum in 100 ⁇ l of blocking solution.
- the plates were washed 5 times after incubation with the phage lysate and then incubated with the serum solution for 60 minutes at 37° C.
- the plates were then washed 5 times and incubated in blocking solution containing human anti-immunoglobulin antibodies conjugated with the enzyme peroxidase (Sigma-Aldrich, USA) diluted 1:10000 and rabbit serum diluted 1:40.
- Phage plaques were transferred from the bacterial medium to nitrocellulose filters (Schleicher & Schuell, Germany) by means of incubation at room temperature for 60 minutes. The filters were blocked for 60 minutes at room temperature in blocking solution (5% skimmed milk powder in PBS, 0.05% Tween-20). 40 ⁇ l of human serum were preincubated with 40 ⁇ l of bacterial extract of BB4 cells, 10 9 wild-type lambda phage particles in 4 ml of blocking solution. After eliminating the blocking solution, the filters were incubated with the serum for 3 hours at room temperature under stirring.
- blocking solution 5% skimmed milk powder in PBS, 0.05% Tween-20
- the filters were then washed 5 times with washing buffer (PBS, 0.05% Tween-20) and then incubated for 60 minutes at room temperature, alternatively with human anti-IgG antibodies conjugated with alkaline phosphatase (Sigma-Aldrich, USA), or with human anti-IgM antibodies conjugated with alkaline phosphatase (Sigma-Aldrich, USA), both diluted 1:7500 in blocking solution.
- washing buffer PBS, 0.05% Tween-20
- human anti-IgG antibodies conjugated with alkaline phosphatase Sigma-Aldrich, USA
- human anti-IgM antibodies conjugated with alkaline phosphatase Sigma-Aldrich, USA
- Phage clones that proved positive at immunoscreening were isolated from the respective phage plaques and then amplified for subsequent characterisation.
- phage clones were analysed by means of phage-ELISA with a substantial panel of positive and negative sera. Clones whose ELISA value exceeded the background value, as obtained from the sum of the mean of the measurements of the negative sera and three times the standard deviation, were judged to be positive.
- Non-Redundant Genbank CDS Non-Redundant Database of Genbank Est Division, Non-Redundant Genbank+EMBL+DDBJ+PDB Sequences.
- the sequences obtained can be classified in four groups:
- the clone Tx-4.11 constitutes a fragment of the antigen GRA1 (Cesbron-Delauw et al., 1989, Proc. Natl. Acad. Sci. USA 86:7537-7541) but has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 26) SGGTGQGLGIGESVDLEMMGNTYRVERPTGNPDLLKIAIKASDGSYSEVGNVNVEEVIDTMKSMQRDEDIFLR ALNKGETVEEAIEDVAQAEGLNSEQTLQLEDAVSAVASVVQDE and its use as a fragment containing an epitope is covered by the present invention.
- the clone TxM-17.2 constitutes a fragment of the antigen GRA2 (Prince et al., 1989, Mol. Biochem. Parasitol., 34: 3-14) but has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 27) YSSPRIVVLIRYCFFSTYRLTMFAVKHCLLVVAVGALVNVSVRAAEFSGVVNQGP and its use a fragment containing an epitope is covered by the present invention.
- the clone Tx-15.11 constitutes a fragment of the gene GRA3 (Bermudes et al., 1994, Mol. Biochem. Parasitol., 68: 247-257) and has never been identified as an antigen in the human antibody response.
- Said clone has the amino acid sequence (SEQ ID No 28) AALGGLAADQPENHQALAEPVTGVGEAGVSPVNEAGESYSSATSG VQEATAPGAVLLDAIDAESDKVDNQAEGGERMKKVEEELSLLRRE LYDRTDRPG and its use as a fragment containing an epitope is covered by the present invention.
- the clone Tx-1.11 constitutes a fragment of the antigen GRA7 (Bon Subscribe et al., 1998, J. Histochem. Cytochem. 46, 1411-1421) and has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 29) FATAATASDDELMSRIRNSDFFDGQAPVDSLRPTNAGVDSKGTDDHLTTSMDKASVESQLPRREPLETEPDEQEEVHF and its use as a fragment containing an epitope is covered by the present invention.
- the clone Tx-8.0 constitutes a fragment of the antigen GRA8 (Kimberly et al., 2000, Mol. Biochem. Parasitol., 105: 25-37) and has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 30) ENPVRPPPPGFHPSVIPNPPYPLGTPAGMPQPEVP and its use as a fragment containing an epitope is covered by the present invention.
- the clone Tx-1.16 constitutes a fragment of the gene MIC3 (Garcia-Réguet et al., 2000, Cellular Microbiol., 2: 353-364) and has never been identified as an antigen in the human antibody response.
- Said clone has the amino acid sequence (SEQ ID No 31) RRTGCHAFRENCSPGRCIDDASHENGYTCECPTGYSREVTSKAEESCVEGVEVTLAEKCEKE FGISASSCKCD and its use as a fragment containing an epitope is covered by the present invention.
- the clone Tx-9.18 constitutes a fragment of the antigen MIC5 (Brydges et al., 2000, Mol. Biochem. Parasitol., 111: 51-66) but has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 32) APTQSEMKEFQEEIKEGVEETKHEDDPEMTRLMVTEKQESKNFSKMAKSQSFSTRIEELGGSISFLTETGVTMIELPKTVSEHDMDQLL H and its use as a fragment containing an epitope is covered by the present invention.
- the clone Tx-7.11 constitutes a fragment of the antigen SAG1 (Burg et al., 1988, J. Immunol., 141:3584-3591) but has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 33) VMASDPPLVANQVVTCPDKKSTAAVILTPTENHFTLKCPKTALTEPPTLAYSPNR QICPAGTTSSCTSKAVTLSSLIPEAEDSWWTGDSASLDTAGIKLTVPI EKFPVTTQTFVVGCIKGDDAQSCMVTVTVQARASSVVNNVARCSYG ADS and its use a fragment containing an epitope is covered by the present invention.
- the clone Tx-4.18 constitutes a fragment of the antigen SAG1 (Burg et al., 1988, J. Immunol., 141:3584-3591) but has never been identified as an “antigen fragment” of the protein in the human humoral response.
- Said clone has the amino acid sequence (SEQ ID No 34) PSVVNNVARCSYGADSTLGPVKLSAEGPTTMTLVCGKDGVKVPQDNNQYCSGTT LTGCNEKSFKDILPKLTENPWQGNASSDKGATLTIKEAFPAESKS VIIGCTGGSPEKHHCTVLLEFAGAAGSAKSA and its use as a fragment containing an epitope is covered by the present invention.
- the plasmid pGEX-SN was constructed by cloning the DNA fragment deriving from the hybridisation of the synthetic oligo-nucleotides K108 5′-GATCCTTACTAGTTTTAGTAGCGGCCGCGGG-3′ (SEQ ID No 35) and K109 5′-AATTCCCGCGGCCGCTACTAAAACTAGTAAG-3′ (SEQ ID No 36) in the BamHI and EcoRI sites of plasmid pGEX-3X (Smith and Johnson, 1988, Gene, 67, 31-40).
- the phage clones for which specific reactivity with sera of patients testing positive for Toxoplasma gondii was demonstrated were amplified and then analysed with a substantial panel of positive and negative sera.
- DNA inserts of clones that showed multiple reactivity with Toxoplasma gondii -positive sera and presented no reactivity with the negative sera were cloned as fusion products with the protein Glutathione Sulphur Transferase (GST) and expressed in the cytoplasma of bacterial cells, for the purposes of determining their specificity and selectivity.
- GST protein Glutathione Sulphur Transferase
- each clone was amplified from a single phage plaque by PCR, using the following oligonucleotides: K47 5′-GGGCACTCGACCGGAATTATCG-3′ (SEQ ID No 37) and K85 5′-GGGTAAAGGTTTCTTTGCTCG-3′ (SEQ ID No 38).
- the resulting fragment was then purified by means of the “Qiagen Purification Kit” (Qiagen, CA, USA), digested with the restriction enzymes SpeI and NotI and cloned in the vector pGEX-SN to generate the fusion with GST.
- the corresponding recombinant proteins were then expressed in E. coli and purified by affinity using Glutathione-Sepharose resin (Amersham Pharmacia Biotech, Sweden) and following standard protocols (Sambrook et al., 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor).
- the following table 3 presents the reactivity with negative and positive sera of a number of the clones selected, assayed in the form of fusion proteins: TABLE 3 Reactivity of GST fusion Reactivity of GST fusion protein Name of protein with positive sera with negative sera clone (pos./total neg.) (neg./total neg.) Tx-4.11 32/40 1/28 Tx-15.11 22/40 0/28 Tx-1.11 27/40 0/28 Tx-8.0 13/40 0/28 Tx-1.16 31/40 0/28 Tx-9.18 3/40 1/28 Tx-7.11 39/40 3/28 Tx-4.18 21/40 1/28 IgG Avidity for Determining the Time of Infection
- IgG avidity is a diagnostic method used to establish the time of infection: IgG avidity is lower during the acute phase of the infection and then tends to increase in the course of time (Hedman et al. 1989 J. Infect. Dis. 159, 736-740). Evaluation of IgG avidity is based on an enzyme-linked immunosorbent assay (ELISA) in which the immunoglobulins are “detached” from the antigen by washing with a urea denaturing solution.
- ELISA enzyme-linked immunosorbent assay
- the plates were blocked with 200 ⁇ l of blocking solution (5% skimmed milk powder in PBS, 0.05% Tween-20) and then washed 5 times with washing buffer (PBS, 0.05% tween-20).
- Serial dilutions of serum (1:50, 1:200, 1:800, 1:3200) in 100 ⁇ l of blocking solution were incubated on plates for 60 minutes at 37° C.
- the plates were then incubated with a denaturing solution of urea 6M in PBS/0.02% Tween-20 for 30 minutes at 37° C.
- the same dilutions of serum were effected and the wells concerned were incubated with normal washing buffer.
- the enzyme activity was measured at optical densities of 405 nm and 620 nm by means of an automatic ELISA OD reader (Multiskan Labsystem, Finland) and the avidity calculation was done according to the mathematical analysis described in the literature (Jenum et al., 1997. J. Clin. Microbiol. 35, 1972-1977).
- the following table 4 gives, by way of examples, the avidity of the human sera for a number of the antigen fragments selected.
- Toxoplasma gondii (10 6 parasites, strain ME49) were grown in vitro in monkey kidney cells (“VERO” African green monkey cells) using DMEM culture medium containing 10% foetal bovine serum, 2 mM glutamine and 0.05 mg/ml gentamicin (Gibco BRL, Canada).
- DMEM culture medium containing 10% foetal bovine serum, 2 mM glutamine and 0.05 mg/ml gentamicin (Gibco BRL, Canada).
- an experimental protocol was used based on the change in pH of the culture medium (Soete et al., 1994, Experimental Parasitology, 78, 361-370).
- the parasites were collected after complete lysis of the host cells and purified by filtration (filter porosity 3 ⁇ m) followed by centrifuging.
- RNA 2 ⁇ g of mRNA were isolated from 5 ⁇ 10 6 parasites using the “QuickPrep Micro mRNA Purification Kit” (Amersham Pharmacia Biotech, Sweden) and following the manufacturer's instructions.
- cDNA was synthesised from 200 ng of poly(A)+ RNA using the “SMART cDNA Library Construction Kit” (Clontech, CA, USA) and following the manufacturer's instructions.
- Genomic DNA was purified from the remaining 5 ⁇ 10 6 cells using standard procedures (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY) and stored at ⁇ 20° C.
- fragments were then purified by means of extraction in phenol/chloroform and subsequent precipitation in ethanol. 500 ng of the resulting DNA were bound with a 20-fold molar excess of “synthetic adaptors” for the purposes of adding the restriction sites SpeI and NotI to the ends of the fragments.
- the excess of unligated adaptors was removed from the ligation mixture by electropheresis on 2% agarose gel and the cDNA fragments with molecular weights ranging from 250 bp to 1000 bp were excised from the gel and purified by means of the “Qiaquick gel extraction kit” (Qiagen, CA, USA) following the manufacturer's instructions.
- the vector ⁇ KM4 was digested with SpeI/NotI and for the construction of the library 6 ligation mixtures were performed, each containing 0.4 ⁇ g of vector and approximately 7 ng of insert. After overnight incubation at 4° C.
- the ligation mixtures were packaged in vitro with the “Ready-To-Go lambda packaging kit” (Amersham Pharmacia Biotech, Sweden) and plated for infection of BB4 cells (bacterial cells of E. coli strain BB4; Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY). After overnight incubation at 37° C. the phage was eluted from the plates with SM buffer (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY), purified, concentrated and stored at ⁇ 80° C. in SM buffer containing 7% dimethylsulphoxide. The complexity of the library calculated as the number of total independent clones with inserts was 10 6 clones.
- the clone TxB-cl26.3 constitutes a fragment of the gene MAG1, a 65 kDa protein of the matrix and wall of T. gondii cysts (Parmley et al., 1994, Molecular and Biochemical Parasitology, 66, 283-296), the protein product of which has never been identified as an “antigen fragment” in the human humoral response.
- Said clone has the amino acid sequence GLSQRVPELPEVEPFDEVGTGARRSGSIATLLPQDAVLYENSEDVAVPSDSASTPSYFHVESPSASVEAATGAVGEVVPDCEE QQEQGDTTLSDHDFH (SEQ ID No 57) and its use as a fragment containing an epitope is covered by the present invention.
- the clone TxB-cl7.1 constitutes a fragment of the gene BAG1, a 30 kDa protein of the heat shock protein family of T. gondii (Bohne et al., 1995, Molecular Microbiology, 16, 1221-1230), the protein product of which has never been identified as an “antigen fragment” in the human humoral response.
- Said clone has the amino acid sequence LNPIDDMLFETALTANEMMEDITWRPRVDVEFDSKKKEMIILADLP GLQKDDVTIEVDNGAIVIKGEKTSKEAEKVDDGKTKNILTERVSGY FARRFQLPSNYIDGISAAMDNGVLRVTIKVEDSGGAKQQISV (SEQ ID No 58) and its use as a fragment containing an epitope is covered by the present invention.
- the phage clones for which specific reactivity with sera of patients testing positive for Toxoplasma gondii was demonstrated were amplified and then analysed with a substantial panel of positive and negative sera. After this ELISA study, the clones that showed multiple reactivity with Toxoplasma gondii -positive sera and presented no reactivity with the negative sera were cloned as fusion products with the protein Glutathione Sulphur Transferase (GST) and expressed in bacterial cells, for the purposes of determining their specificity and selectivity.
- GST protein Glutathione Sulphur Transferase
- each clone was amplified from a single phage plaque by PCR, using the following oligonucleotides: K47 5′-GGGCACTCGACCGGAATTATCG-3′ (SEQ ID No 37) and K85 5′-GGGTAAAGGTTTCTTTGCTCG-3′ (SEQ ID No 38).
- the resulting fragment was then purified by means of the “Qiagen Purification Kit” (Qiagen, CA, USA), digested with the restriction enzymes SpeI and NotI and cloned in the vector pGEX-SN to generate the fusion with GST.
- the corresponding recombinant proteins were then expressed in E. coli and purified by affinity using Glutathione-Sepharose resin (Amersham Pharmacia Biotech, Sweden) and following standard protocols (Sambrook et al., 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor).
- an affinity selection procedure was used consisting of two “panning” cycles with four sera collected from infants who were congenitally infected by the parasite, followed by an immunological screening procedure carried out with the same sera.
- the library was selected with sera T1, T2, T3, T4, generating, after a single selection cycle, the corresponding mixtures p1 I , p2 I , p3 I and p4 I .
- Each mixture was then subjected to a second affinity selection cycle with the same serum, giving rise to a second series of mixtures (called p1 II p2 II , p3 II and p4 II ).
- Various positive clones were identified by means of immunoplate screening per plaque of reactive mixtures.
- Phage-Elisa, immunoscreening, and the preparation of phage clones were subsequently performed exactly as described in Examples 1 and 2.
- the following table 8 gives, by way of examples, the reactivity of a number of the recombinant bacteriophages selected.
- TABLE 8 Reactivity of phage Reactivity of phage clone with clone with positive sera negative sera (negative/total Name of clone (positive/total positive) negative) Tx-2.a 13/16 0/10 Tx-1.b 11/16 0/10 Tx-11.b 12/16 0/10 Tx-13.b 9/16 0/10 Tx-15.b 9/16 0/10 Characterisation of Positive Clones
- the clones Tx-2.a e Tx-1.b represent two distinct fragments of the MIC2 gene (Wan et al, 1997, Mol. Biochem. Parasitol. 84: 203-214) and have never been identified as antigens of the human antibody response.
- Said clones have respectively the amino acid sequences PQDAICSDWSAWSPCSVSCGDGSQIRTRTEVSAPQPGTPTCPDCPA PMGRTCVEQGGLEEIRECSAGVCAVDAGCGVWV (SEQ ID No 64) and PCPINATCGQFEEWSTCSVSCGGGLKTRSRNPWNEDQQHGGLSCE QQHPGGRTETVTCNPQACPVDERPGEWAEWGECSVTCGDGVRER RRGKSLVEAIFGGRTIDQQNEALPEDLKIKNVEYEPCSYPACGASC TYVWSDWNK (SEQ ID No 65) and their use as fragments containing an epitope is covered by the present invention.
- the clone Tx-11.b represents a distinct fragment of the M2AP gene (Rabenau et al., 2001, Mol. Microbiol. 41: 537-547) and has never been identified as antigen of the human antibody response.
- Said clone has the amino acid sequence NEPVALAQLSTFLELVEVPCNSVHVQGVMTPNQMVKVTGAGWDNGVLEFYVTRPTKTGGDTSRSHIASIMCYSK DIDGVPSDKAGKCFLKNFSGEDSSEIDEKEVSLPIKSHNDAFMFVC SSNDGSALQCDVFALDNTNSSDGWKVNTVDLGVSVSPDLAFGLTA DGVKVLYASSGLTAINDDPSLGCKAPPHSPPAGEEPSLPSPENS GSATPAEESPSESES (SEQ ID No 66) and its use as fragment containing an epitope is covered by the present invention.
- the clone Tx-13.b represents a fragment of the AMA1 gene (Hehl et al., 2000, Infect. Immun. 68:7078-7086).
- Said clone has the amino acid sequence LRGYRFGVWKKGRCLDYTELTDTVIERVESKAQCWVKTFENDGVASDQPHTYPLTSQASWNDWWPLHQSDQPHSGGVGRNYG FYYVDTTGEGKCALSDQVPDCLVSDSAAVSYTAAGSLSEETPNFIIP SNPSVTPPTPETALQCTADKFPDSFGACDVQACKRQKTSCVGGQIQ STSVDCTADEQNECGSNTA (SEQ ID No 67) and its use as fragment containing an epitope is covered by the present invention.
- the clone Tx-15.b represents a fragment of the MIC4 gene (Brecht et al., 2001, J. Biol. Chem. 276:4119-4127).
- Said clone has the amino acid sequence SANVTSSEPAKLDLSCAHSDNKGSRAPTIGEPVPDVSLEQCAAQCKAVDGCTHFTYNDDSKMCHVKEGKPDLYDLTGGKTAPRS CDRSCFEQHVSYEGAPDVMTAIVTSQSADCQAACAADPSCEIFTY NEHDQKCTFKGRGFSAFKERGVLGVTSGPKQFCDEGGKLT (SEQ ID No 68) and its use as fragment containing an epitope is covered by the present invention.
- Phage clones isolated from the microneme-library were cloned as fusion products with GST protein and expressed in bacterial cells, for the purposes of determining their specificity and selectivity. The procedure described in Examples 1 and 2 was used to produce the fusion proteins.
- the following table 10 presents the reactivity with negative and positive sera of a number of the clones selected, assayed in the form of fusion proteins: TABLE 10 Reactivity of GST fusion Reactivity of GST fusion protein with positive sera portein with negative sera Name of clone (pos./total neg.) (neg./totale neg.) Tx-2.a 29/30 0/15 Tx-1.b 15/30 0/15 Tx-11.b 23/30 0/15 Tx-13.b 24/30 0/15 Tx-15.b 12/30 0/15
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention described herein relates to a method for identifying antigen fragments of Toxoplasma gondii proteins, and their use as diagnostic and immunogenic agents. Said method is implemented by means of selection of DNA fragments libraries of the parasite with sera of subjects who have been infected, using the phage display technique, and is characterised in that it uses the expression/exposure vector λKM4. The method allows also to identify antigen fragments related to the time of the infection.
Description
- This application is a divisional of Ser. No. 10/508,622, filed Dec. 10, 2004, which is a U.S. national phase of international application PCT/IT03/00162, filed Mar. 18, 2003, which designated the U.S. and claims benefit of IT Application No. RM02A000159, filed Mar. 21, 2002 and IT Application No. RM02A000568, filed Nov. 13, 2002, the entire contents of each of which is incorporated herein by reference.
- The invention described herein relates to a method for identifying antigen fragments of Toxoplasma gondii proteins, and their use as diagnostic and immunogenic agents. Said method is implemented by means of selection of cDNA libraries of the parasite or of DNA fragments of specific genes of the parasite with sera of subjects who have been infected by the parasite, using the phage display technique, and is characterised in that it uses the vector λKM4.
- The invention described herein also relates to the technical field of the preparation of diagnostic means not applied directly to the animal or human body and furnishes compounds, methods for their preparation, methods for their use and compositions containing them which are suitable for industrial application in the pharmaceutical and diagnostic field, particularly for the detection and diagnosis of Toxoplasma gondii infections, as well as for the treatment and prevention of said infections.
- Early diagnosis is a priority and highly desirable objective in all fields of medicament, particularly because it allows an appreciable improvement in the patient's life and a concomitant saving on the part of health care systems or on the part of the actual patients. In the particular case of the invention described herein, early diagnosis is that of potential or existing Toxoplasma gondii infection in pregnant women, with particular concern for the health of the foetus, and in infected subjects, particularly those with impaired immunity.
- Toxoplasma gondii is an obligate intracellular parasite that infects all mammalian cells, including those of human subjects (McCabe and Remington, N. Engl. J. Med. 1988, 318-313-5), and other animal genera, e.g. birds. The life cycle of the parasite is complex and one may distinguish between three stages of infection: tachyzoite (asexual), bradyzoite (in tissue cysts, asexual) and sporozoite (in oocysts, sexual reproduction). Transmission typically occurs through ingestion of undercooked meat harbouring tissue cysts or vegetables contaminated with oocysts shed by cats. Human infection is generally asymptomatic and self-limiting in immunocompetent hosts. In contrast, in subjects with impaired immunity (particularly those affected by AIDS), toxoplasmosis is a severe opportunist infection, which may give rise to encephalitis with very serious outcomes (Luft, B. J., Remington J. S., 1992, Clin. Infect. Dis. 15, 211-22). Moreover, contracting primary infection during pregnancy may lead to miscarriages or to severe foetal disease in mammals.
- For an extensive overview of the problem of toxoplasmosis the reader is referred to the specialistic medical literature.
- Diagnosis of T. gondii infection is established by isolating the micro-organism in the blood or body fluids, identifying the parasite in tissues, detecting specific nucleotide sequences with PCR, or by detecting specific anti-T. gondii immunoglobulins produced by the host in response to the infection (Beaman et al., 1995 Principles and Practice of Infectious Diseases 4th Ed., Churchill Livingstone Inc., New York, 2455-75; Remington J S et al. 1995, Infectious Diseases of the Fetus and Newborn Infant, W.B. Saunders, Philadelphia, Pa., 140-267).
- One of the main problems in diagnosing T. gondii infections has to do with pregnant women. To implement suitable therapies in good time and avoid possible damage to the foetus it is very important to establish if parasitic infection occurred before or after conception. This is generally done by attempting to detect the presence of the various classes of anti-Toxoplasma immunoglobulins (IgG, IgM, IgA, avidity of IgG). For this reason, the availability of specific, sensitive diagnostic agents is desirable.
- T. gondii antigens have long been known and available, first of all as antigen mixtures obtained in various ways (FR 2,226,468, Meriéux; SU 533376, Veterinary Research Institute; JP 54044016, Nihon Toketsu Kanso), then as subsequent isolations of pure antigens (EP 0 082 745, Merieux; EP 0 301 961, INSERM, Pasteur; WO 89/5658, Transgene) and their characterisation both as proteins, and of their respective genes (WO 89/08700, U. Leland, Dartmouth Coll.; U.S. Pat. No. 4,877,726, Res. Inst. Palo Alto; WO 89/12683, INSERM, Pasteur; EP 0 391 319, Mochida Pharm.; IT 1,196,817, CNR; EP 0 431 541, Behringwerke; WO 92/01067, CNRS; WO 92/02624, U. Flinders; WO 92/11366, Innogenetics, Smithkline Beecham; U.S. Pat. No. 5,215,917, Res. Inst. Palo Alto; WO 92/25689, FR 2702491, INSERM, Pasteur; WO 96/02654, bioMeriéux, Transgene; EP 0 710 724 Akzo; EP 0 724 016, bioMeriéux; EP 0 751 147, Behringwerke; U.S. Pat. No. 5,633,139, Res. Inst. Palo Alto; WO 97/27300, Innogenetics; U.S. Pat. No. 5,665,542, U.S. Pat. No. 5,686,575, Res. Inst. Palo Alto; WO 99/32633, Heska; JP 11225783, Yano; WO 99/61906, Abbott; WO 99/66043, Smithkline Beecham; JP 2000300278, Yano; WO 00/164243, Virsol).
- Numerous studies have found various different antigenic proteins of T. gondii and the gene sequences of these have also been determined.
- Among the most interesting proteins both for diagnostic and therapeutic purposes, in the form of vaccines, we should mention: the surface antigens SAG1 (or P30) (WO 89/08700, Stanford University; WO 89/12683 Pasteur, INSERM; WO 94/17813, WO 96/02654, Transgene, bioMeriéux; EP 0 724 016, WO 99/61906, U.S. Pat. No. 5,962,654, Harning et al., Clinical and Diagnostic Laboratory Immunology, May 1996, 355-357); SAG2 (or P22) (Parmley et al., 1992, J. Clin. Microbiol. 30, 1127-33); the dense granule proteins GRA1 (or P24) (EP 0 301 961, Pasteur, INSERM; WO 89/05658, Transgene, Cesbron-Delauw, et al., 1989 P.N.A.S. USA 86, 7537-41); GRA2 (or P28) (WO 93/25689, INSERM, Pasteur; U.S. Pat. No. 5,633,139, U.S. Pat. No. 5,665,542, U.S. Pat. No. 5,686,575, Res. Inst. Palo Alto; Prince et al., Mol. Biochem. Parasitol., 34 3-14); GRA4 (Mevelec et al., Mol. Biochem. Parasitol. 56, 227-38); GRA6 (or P32) (FR 2,702,491, INSERM, Pasteur; Lecordier al., Mol. Biochem. Parasitol. 70, 85-94); GRA7 (WO 99/61906, Abbott; Jacobs et al., Mol. Biochem. Parasitol. 91, 237-49); GRA3 (Robben et al. 2002, J. Biol. Chem. 277, 17544-47): the rhoptry antigens ROP1 (or P66) (U.S. Pat. No. 5,976,553, U. Leland; EP 0 431 541, Innogenetics); ROP2 (or P54) (Sharma et al., J. Immunol., 131, 377-83).
- As described in the above-mentioned references, the antigens were obtained with well-known recombinant cDNA techniques in expression vectors. For example, for the antigen SAG1, WO 98/08700 uses known expression vectors in phage λgt11. WO 98/12683 uses the same phage and transfects E. coli with a proprietary plasmid, or by preparing a special expression cassette, as in WO 96/02654. EP 0 724 016 obtains mimotypes, using combinatorial expression libraries of peptides. EP 0 301 961 describes how to obtain excretion-secretion antigens with molecular weights ranging from 20 kDa to 185 kDa. WO 89/05658 describes a protein containing the epitopes of the 24 kDa protein recognised by the antibodies produced against Toxoplasma excretion-secretion antigens; this protein is obtained by transfection of cells by means of expression vectors. The antigen P28 (GRA2) is described in U.S. Pat. No. 5,633,139 and the method of obtaining it is again implemented through expression in phage λgt11. The antigen P32 (GRA6) is described in patent FR 2,702,491, the antigen ROP1 (P66) in U.S. Pat. No. 5,976,553, P35 (or GRA8) in EP 0 431 541, WO 99/57295 and WO 99/61906, and lastly P68 in EP 0 431 541.
- It should be stressed that all these antigens are obtained by means of molecular biology techniques that use the expression of proteins in bacterial cells. None of the documents cited describe the technique of expression/exposure of libraries of cDNA deriving from Toxoplasma gondii in the lambda phage (phage display) to obtain fragments of antigens of the pathogen.
- The invention described herein uses a new vector of DNA expression and protein exposure as molecular fusion with the amino-terminal part of protein D of the lambda bacteriophage capsid (pD) (λKM4).
- The expression/exposure vector was described for the first time in patent application PCT/IT01/00405, filed on Jul. 26, 2001, the most important part of which is incorporated herein. This vector, called λKM4, differs from that used in expression only experiments (λgt11) in that the recombinant protein coded for by the DNA fragment is expressed as fusion with a protein of the bacteriophage itself and then exposed on the capsid. According to the vector project, the phage exposes the protein fragment on the surface only if its open reading frame (ORF) coincides with pD. The size of the fragments of DNA cloned in our libraries was selected in order to represent a population of medium size ranging from 300 to 1000 nucleotide base pairs (bp), and, for statistical reasons, most of the out-of-frame sequences contain stop codons which do not permit their translation and consequently exposure on the surface of the phage.
- It has now been found that the combination of the affinity selection and phage display techniques, together with the use of the vector λKM4, provides a method for the identification of specific antigen fragments of Toxoplasma gondii by means of the selection of display libraries of DNA fragments with sera of infected individuals. DNA fragments are obtained either from cDNA of whole parasite or from DNA encoding for known specific gene products. With this method it proves possible to identify antigen fragments from very large libraries (i.e. expressing a large number of different sequences). The antigen fragments thus identified enable specific ligands to be obtained, which in turn can be used as diagnostic and therapeutic means.
- Therefore, one object of the invention described herein is a method for the identification of antigen fragments of Toxoplasma gondii proteins, by means of the selection of libraries of DNA fragments with sera of subjects who have been infected by the parasite, using the phage display technique, characterised in that it uses the vector λKM4.
- Another object of the present invention are antigen fragments obtainable with the above-mentioned method, both isolated and characterised, and as sets of antigen fragments called “collections”. The invention described herein also extends to the antigen portions of said fragments (epitopes).
- The use of said antigen fragments as diagnostic agents and the related diagnostic aids containing them, for example in the form of kits or other supports, constitute a further object of the present invention.
- The use of said antigen fragments as active agents, particularly with an immunogenic action, for the preparation of medicaments for the prevention and therapy of Toxoplasma gondii infection, constitute a further object of the present invention.
- Another object of the present invention are the gene sequences coding for the above-mentioned antigen fragments, their use as medicaments, particularly for the prevention and therapy of Toxoplasma gondii infection, e.g. as gene therapy. The present invention also extends to the gene sequences that hybridise with the sequences of the above-mentioned fragments in stringent hybridisation conditions.
- Another object of the present invention are anti-epitope antibodies and their use in the preparation of diagnostic, preventive and therapeutic means, e.g. as conjugates with active ingredients such as chemo-therapy agents. Antibodies can be generated also against collections of said epitopes.
- The method provided by the present invention makes it possible to confirm the use of the Toxoplasma gondii antigens described above as such as diagnostic agents and also to identify in known antigens the epitopes that trigger an immune response in human subjects; this portion is a further object of the present invention; but it also makes it possible to identify the antigenic function of proteins of Toxoplasma gondii, or of portions thereof, which, though their structure and possibly their physiological function may be known, are unknown as regards their antigenic function, and such function comes within the framework of the present invention; lastly, the method according to the present invention also provides new antigen fragments of Toxoplasma gondii proteins, that constitute yet another object of the present invention.
- Another object of the present invention is the use of the antigen fragments thus identified for the preparation of means of diagnosing the infection, as well as the actual diagnostic means containing them. The use realtes also to the diagnosis of the time of the infection, in particular by the IgG avidity assay.
- Another object of the present invention is the use of the antigen fragments thus identified as medicaments, particularly for the preparation of formulations, and particularly in the form of vaccines, which are useful for the prevention and cure of the infection. The vaccines according to the present invention are suitable for use in humans and other animals (particularly pigs, cats, sheeps).
- Another object of the present invention are ligands generated from the above-mentioned antigen fragments and the related collections and the use of such ligands for the preparation of diagnostic means for the detection of the infection, with particular reference to the time of infection, as well as therapeutic means for the prevention and treatment of the infection itself.
- Another object of the present invention is a method for the diagnosis of Toxoplasma gondii infection, comprising the selection of sera of subjects affected or suspected of being affected by said infection with the above mentioned antigen fragments and/or their collection and/or at least one ligand and/or antibody.
- These and other objects will be illustrated here below in detail, also by means of examples and figures, where
FIG. 1 represents the map of the vector λKM4. - The present invention comprises the construction of expression/exposure libraries of DNA fragments prepared from Toxoplasma gondii cells, the selection of such libraries with the sera of patients who have been infected by Toxoplasma gondii, the characterisation of the antigen fragments, and the use of said fragments for developing selective diagnostic means.
- Optionally, the present invention may entail the generation of specific ligands for said antigen fragments (e.g. human recombinant antibodies or humanised murine recombinant antibodies) and the construction of selective diagnostic means that incorporate the ligands generated.
- Antibodies and ligands of the present invention can be obtained according according to the general common knowledge and conventional methods.
- The method according to the present invention advantageously combines affinity selection and the power of phage display.
- What is meant by phage display, as understood by the person of ordinary skill in the art, is a strategy based on the selection of expression/exposure libraries in which small protein domains are exposed on the surface of bacteriophages containing the corresponding genetic information.
- The method implemented according to the present invention for the first time provides new and advantageous analysis possibilities:
-
- the use of small amounts of serum to identify antigen fragments of the infectious agent,
- the possibility of selecting only the domains responsible for the interaction with the antibodies, without having to express the entire gene, the product of which may be insoluble or toxic;
lastly, the possibility of effecting successive cycles of selection using sera from different patients or mixtures of sera facilitates the identification of cross-reactive antigens which represent one of the main objectives of the present invention.
- For the above-mentioned reasons, for each library, messenger RNA was purified from an adequate number of cells (e.g. 106 cells), using common commercially available means, from which the corresponding cDNA was generated. The latter was fragmented (by means of the bacterial enzyme DNaseI) and then cloned in the expression/exposure vector λKM4 (see example).
- In the other embodiment, relating to specific T. gondii gene, each specific T. gondii gene, was amplified from the DNA of the parasite (either cDNA or genomic DNA, both prepared by using common commercially available kits) by means of PCR with specific synthetic oligonucleotides. DNA of single genes was then fragmented randomly by means of the bacterial enzyme DNaseI and then cloned as a pool in the expression/exposure vector λKM4.
- The amplification of the libraries was done by means of normal techniques with which the expert in the field is familiar, e.g. by plating, growth, elution, purification and concentration (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY). The libraries were then used to develop the selection conditions, screening and characterisation of the sequences identified. Lastly, the phage clones identified were characterised by immunoenzymatic assays.
- A library of the phage display type, constructed using cDNA deriving from cells of pathogenic organisms, makes it possible to exploit affinity selection, which is based on incubation of specific sera (reactive with the pathogen) with collections of bacteriophages that express portions of proteins of the pathogen on their capside and that contain the corresponding genetic information. The bacteriophages that specifically bind the antibodies present in the serum are easily recovered, remaining bound (by the antibodies themselves) to a solid support (e.g. magnetic beads); the non-specific ones, by contrast, are washed away. Direct screening, i.e. the analysis of the ability of single phage clones to bind the antibodies of a given serum, is done only at a later stage, when the complexity of the library (i.e. the different number of sequences) is substantially reduced, precisely as a result of the selection.
- The use of selection strategies allows faster analysis of a large number of different protein sequences for the purposes of identifying those that respond to a particular characteristic, e.g. interacting specifically with antibodies present in the serum of patients who have been infected by the pathogen. What is more, the combination of affinity selection and phage display makes it possible to use a smaller amount of serum for each analysis. The direct screening of a classic cDNA library, in fact, entails the use of large amounts of serum, which are not always easy to obtain. For example, to analyse a library of approximately 106 independent clones it would be necessary to incubate along with the preselected serum the numerous filters containing a total of approximately 107 phage plaques transferred from the different culture plates with the infected bacteria (e.g. a serum volume of 1-10 ml). The use of a display-type library, on the other hand, permits affinity selection in small volumes (0.1-1 ml) prior to direct screening, and from limited amounts of serum, such as, for example, 10 μl.
- Lastly, given that a very large number of bacteriophages can be contained in small volumes (e.g. 1011 phage particles are normally contained in a volume of 0.1 ml), and affinity selection is done in small volumes (0.1-1 ml), a further advantage of the use of display-type libraries consists in analysing a number of independent clones (particles of recombinant phages exposing different cDNA sequences on their surfaces) 10-100 times greater (e.g. 108 different bacteriohages) than expression-alone libraries where, as a result of technical problems, not more than 106 independent clones are normally analysed.
- As regards industrial applicability, one possible realisation of the present invention is in the form of diagnostic kits containing the antigen fragments and/or ligands and/or antibodies described above.
- The diagnostic kits which are the object of the present invention are known to the expert in the field and do not require any particular description. By way of an example, the reader is referred to the patent literature cited above, to which may be added U.S. Pat. No. 6,265,176 and WO 01/63283 as further references.
- Similar considerations hold good for the therapeutic application, where the preparation of medicaments or vaccines comes within the framework of general knowledge; for further reference purposes the reader is again referred to the patent literature cited in the present description.
- The invention will now be illustrated in greater detail by means of examples and figures, where
FIG. 1 presents the map of the vector λKM4. - This technique is described in international patent application No PCT/IT01/00405, filed on Jul. 26, 2001 and incorporated herein for reference purposes, explicitly mentioning the references cited therein.
FIG. 1 represents the map of the vector λKM4. The plasmid pNS3785 (Sternberg and Hoess, 1995, Proc. Natl. Acad. Sci. USA., 92:1609-1613) was amplified by inverse PCR using thesynthetic oligonucleotides 5′-TTTATCTAGACCCAGCCCTAGGAAGCTTCTCCTGAGTAGGACAAATCC-3′ (SEQ ID No 1) bearing the sites XbaI and AvrII (underlined) for the subsequent cloning of the lambda phage, and 5′-GGGTCTAGATAAAACGAAAGGCCCAGTCTTTC-3′ (SEQ ID No 2) bearing the site XbaI. In inverse PCR a mixture of Taq DNA polymerase and Pfu DNA polymerase was used to increase the fidelity of the DNA synthesis. Twenty-five amplification cycles were performed (95° C.—30 sec, 55° C.—30 sec, 72° C.—20 min). The autoligation of the PCR product, previously digested with XbaI endonuclease gave rise to the plasmid pKM3. The lambda gene pD was amplified with PCR from the plasmid pNS3785 using theprimers 5′-CCGCCTTCCATGGGTACTAGTTTTAAATGCGGCCGCACGAGCAAAGAAACCTTTAC-3′ (SEQ ID No 3)e 5′-AGCTTCCTAGGGCTGGGTCTAG-3′ (SEQ ID No 4) containing the restriction sites NcoI, SpeI, NotI and EcoRI, respectively, (underlined). The PCR product was then purified, digested with NcoI and EcoRI endonuclease and recloned in sites NcoI and EcoRI of pKM3, resulting in the plasmid pKM4 bearing only the restriction sites SpeI and NotI at the 5′ end of the protein gpD. The plasmid was then digested with XbaI endonuclease and cloned in the XbaI site of the lambda phage Dam15imm21nin5 (Sternberg and Hoess, 1995, Proc. Natl. Acad. Sci. USA., 92:1609-1613). - Construction of cDNA Library from Tachyzoites of Toxoplasma gondii
- Tachyzoites of the protozoon Toxoplasma gondii (RH strain) were grown in vitro in monkey kidney cells (“VERO” African green monkey cells) using DMEM culture medium containing 10% foetal bovine serum, 2 mM glutamine and 0.05 mg/ml gentamicin (Gibco BRL, Canada). The parasites were collected after complete lysis of the host cells and purified by filtration (filter porosity 3 μm) followed by centrifuging. 4 μg of mRNA were isolated from 107 tachyzoites using the “QuickPrep Micro mRNA Purification Kit” (Amersham Pharmacia Biotech, Sweden) and following the manufacturer's instructions. The double-helix cDNA was synthesised from 200 ng of poly(A)+ RNA using the “SMART cDNA Library Construction Kit” (Clontech, CA, USA) and following the manufacturer's instructions. 10 μg of total cDNA were then fragmented randomly using 0.5 ng of the endonuclease DNaseI (Sigma-Aldrich, USA). The mixture of cDNA and DNaseI was incubated for 20 minutes at 15° C. and the cDNA fragments were purified with extraction in phenol/chloroform and subsequent purification by means of the “QIAquick PCR Purification Kit” (Qiagen, CA, USA), following the manufacturer's instructions. The 3 μg ends of the cDNA fragments were “flattened” by incubating the DNA with 9 units of the enzyme T4 DNA polymerase (New England Biolabs, MA, USA) for 60 minutes at 15° C. The fragments were then purified by means of extraction in phenol/chloroform and subsequent precipitation in ethanol. 500 ng of the resulting DNA were bound with a 20-fold molar excess of “synthetic adaptors” for the purposes of adding the restriction sites SpeI and NotI to the ends of the fragments. Six adaptors were used, obtained by hybridisation of the following pairs of oligonucleotides:
K185 5′-CTAGTCGTGCTGGCCAGC-3′ (SEQ ID No 5) andK186 5′-GCTGGCCAGCACGA-3′ (SEQ ID No 6);K187 5′-CTAGTCGTGCTGGCCAGCT-3′ (SEQ ID No 7) andK188 5′-AGCTGGCCAGCACGA-3′ (SEQ ID No 8);K189 5′-CTAGTCGTGCTGGCCAGCTG-3′ (SEQ ID No 9) andK190 5′-CAGCTGGCCAGCACGA-3′ (SEQ ID No 10);K191 5′-TCTGGTGGCGGTAGC-3′ (SEQ ID No 11) andK192 5′-GGCCGCTACCGCCACCAGA-3′ (SEQ ID No 12);K193 5′-TTCTGGTGGCGGTAGC-3′ (SEQ ID No 13) andK194 5′-GGCCGCTACCGCCACCAGAA-3′ (SEQ ID No 14);K195 5′-TTTCTGGTGGCGGTAGC-3′ (SEQ ID No 15) andK196 5′-GGCCGCTACCGCCACCAGAAA-3′ (SEQ ID No 16). The excess of unligated adaptors was removed from the ligation mixture by electrophoresis on 2% agarose gel and the cDNA fragments with molecular weights ranging from 300 bp to 1000 bp were excised from the gel and purified by means of the “Qiaquick gel extraction kit” (Qiagen, CA, USA) following the manufacturer's instructions. The vector λKM4 was digested with SpeI/NotI and for the construction of the library 6 ligation mixtures were performed, each containing 0.4 μg of vector and approximately 7 ng of insert. After overnight incubation at 4° C. the ligation mixtures were packaged in vitro with the “Ready-To-Go lambda packaging kit” (Amersham Pharmacia Biotech, Sweden) and plated for infection of BB4 cells (bacterial cells of E. coli strain BB4; Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY). After overnight incubation at 37° C. the phage was eluted from the plates with SM buffer (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY), purified, concentrated and stored at −80° C. in SM buffer containing 7% dimethylsulphoxide. The complexity of the library calculated as the number of total independent clones with inserts was 107 clones. - Affinity Selection
- Two distinct methods were used for selecting the phage library with human sera. In the first method 100 μl of magnetic beads coated with Protein G (Dynabeads Protein-G, Dynal, Norway) were incubated with 10 μl of human serum for 30 minutes at room temperature. The beads were then incubated for 1 hour at 37° C. with blocking solution consisting of: 5% skimmed milk powder in PBS (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY), 0.05% Tween 20, and MgSO4 10 mM. Approximately 1010 phage particles of the library were added to the beads and diluted in 1 ml of blocking solution for a further 4-hour incubation at room temperature with weak stirring. In the second method 40 μl of “M280-Tosyl activated” magnetic beads (Dynal, Norway) were coated with human anti-IgM antibodies (Sigma-Aldrich, USA) following the manufacturer's instructions. The beads were then washed with PBS/TritonX-100 1% and incubated with 10 μl of human serum in 300 μl of blocking solution for 2 hours at room temperature. After washing the beads three times with washing solution (PBS, 1% TritonX100, 10 mM MgSO4), 1010 phage particles of the library were added to the beads and diluted in 200 μl of blocking solution for a further 3-hour incubation at room temperature with weak stirring.
- With both selection methods, the beads were washed 10 times with 1 ml of washing solution (PBS, 1% TritonX100, 10 mM MgSO4). The bound bacteriophages were amplified for infection of BB4 cells added directly to the beads (1.2 ml per selection) and subsequent 30-minute incubation at room temperature. 12 ml of NZY-Top Agar (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY) were added to the mixture of beads and cells and immediately poured onto NZY plates (2 15-cm Petri capsules for selection). The plates were incubated for 12-16 hours at 37° C. The next day the phages were collected from the plates by means of the addition of 15 ml of SM buffer per plate and stirring for 4 hours at room temperature. The phages were purified by precipitation in PEG/NaCl (20% polyethylene glycol, NaCl 1M) and finally resuspended in 5 ml of SM and stored at +4° C.
- Selection of the Library with Human Sera
- To identify the specific antigens of T. gondii an affinity selection procedure was used consisting of two “panning” cycles with one or more positive sera (that is to say sera deriving from a patient who tested positive for the presence of antibodies directed against the parasite), followed by an immunological screening procedure carried out with the same sera or, alternatively, by analysis of single clones taken at random from the mixture of selected phages. Preferably, the library was selected with 10 positive sera (T1, T2, T3, T4, T5, T6, T7, T8, T9 and T10), generating, after a single selection cycle, the corresponding mixtures p1I, p2I, p3I, p4I, p5I, p6I, p7I, p8I, p9I and p10I. Each mixture was then subjected to a second affinity selection cycle with the same serum, according to the first strategy mentioned above, giving rise to a second series of mixtures (called p1II, p2II, p3II, p4II, p5II, p6II, p7II, p8II, p9II and p10II). The initial characterisation by means of an enzyme-linked immunosorbent assay (Phage-ELISA) showed that some of the mixtures were more reactive with the corresponding serum used for the selection, thus confirming the efficacy of the library and the affinity selection procedure. Various positive clones were identified by means of immunoplate screening per plaque of reactive mixtures.
- Phage-ELISA
- Multi-well plates (Immunoplate Maxisorb, Nunc, Denmark) were coated, incubating 100 μl/well of anti-lambda polyclonal antibodies overnight at 4° C. with a concentration of 0.7 μg/ml in NaHCO3 50 mM, pH 9.6. After eliminating the coating solution, the plates were incubated with 250 μl of blocking solution (5% skimmed milk powder in PBS, 0.05% Tween-20). The plates were then washed twice with washing buffer (PBS, 0.05% Tween-20). A mixture of 100 μl of blocking solution containing phage lysate (diluted 1:1) was added to each well and incubated for 60 minutes at 37° C. 1 μl of human serum was preincubated for 30 minutes at room temperature with 109 wild-type phage particles, 1 μl of rabbit serum, 1 μl of bacterial extract of BB4 cells, 1 μl of foetal bovine serum in 100 μl of blocking solution. The plates were washed 5 times after incubation with the phage lysate and then incubated with the serum solution for 60 minutes at 37° C. The plates were then washed 5 times and incubated in blocking solution containing human anti-immunoglobulin antibodies conjugated with the enzyme peroxidase (Sigma-Aldrich, USA) diluted 1:10000 and rabbit serum diluted 1:40. After 30 minutes' incubation the plates were washed 5 times and the peroxidase activity was measured with 100 μl of TMB liquid substrate (Sigma-Aldrich, USA). After 15 minutes' development, the reaction was stopped by adding 25 μl of H2SO4 2M. Lastly, the plates were analysed using an automatic ELISA reader (Multiskan, Labsystem, Finland) and the results were expressed as OD=OD450nm-OD620nm. The ELISA data were assessed as mean values of two independent assays.
- Immunoscreening
- Phage plaques were transferred from the bacterial medium to nitrocellulose filters (Schleicher & Schuell, Germany) by means of incubation at room temperature for 60 minutes. The filters were blocked for 60 minutes at room temperature in blocking solution (5% skimmed milk powder in PBS, 0.05% Tween-20). 40 μl of human serum were preincubated with 40 μl of bacterial extract of BB4 cells, 109 wild-type lambda phage particles in 4 ml of blocking solution. After eliminating the blocking solution, the filters were incubated with the serum for 3 hours at room temperature under stirring. The filters were then washed 5 times with washing buffer (PBS, 0.05% Tween-20) and then incubated for 60 minutes at room temperature, alternatively with human anti-IgG antibodies conjugated with alkaline phosphatase (Sigma-Aldrich, USA), or with human anti-IgM antibodies conjugated with alkaline phosphatase (Sigma-Aldrich, USA), both diluted 1:7500 in blocking solution. After washing the
filters 5 times, 5 ml of development solution (substrates BCIP and NBT, Sigma-Aldrich, USA) were added and the development was interrupted by washing the filters in water. - Preparation of the Lambda Phase from Lysogenic Cells
- Phage clones that proved positive at immunoscreening (direct screening) were isolated from the respective phage plaques and then amplified for subsequent characterisation. The bacterial BB4 cells were grown under stirring at 37° C. up to an optical density OD600=1.0 in LB culture medium (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY) containing 0.2% maltose and 10 mM MgSO4, recuperated by centrifuging and resuspended in SM buffer at optical density OD600=0.2. 100 μl of cells were infected with recombinant bacteriophages recovered from single plaques, incubated for 20 minutes at room temperature, plated on LB medium with ampicillin (100 μg/ml) and then incubated for 18-20 hours at 32° C. A single bacterial colony was then grown in 10 ml of LB/ampicillin overnight at 32° C. under stirring. 500 ml of LB/ampicillin and MgSO4 10 mM were added to 5 ml of the overnight culture and incubated at 32° C. up to an optical density OD600=0.6 under vigorous stirring. The culture was then incubated for 15 minutes in a water bath at 45° C. and then at 37° C. for a further 3 hours. After this, the bacteriophages were purified of the bacterial culture according to standard procedures (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY) and stored at +4° C.
- Lastly, the phage clones were analysed by means of phage-ELISA with a substantial panel of positive and negative sera. Clones whose ELISA value exceeded the background value, as obtained from the sum of the mean of the measurements of the negative sera and three times the standard deviation, were judged to be positive.
- The following table 1 gives, by way of examples, the reactivity of a number of the recombinant bacteriophages selected.
TABLE 1 Reactivity of phage Reactivity of phage clone clone with positive with negative sera Name of clone sera (positive/total pos.) (negative/total neg.) Tx-4.11 13/21 0/10 TxM-17.2 4/8 1/8 Tx-15.11 11/21 0/10 Tx-1.11 19/21 0/10 Tx-8.0 6/21 0/10 Tx-1.16 20/21 0/10 Tx-9.18 9/21 0/8 Tx-7.11 21/21 0/10
Characterisation of Positive Clones - The clones which showed multiple reactivity with the Toxoplasma gondii positive sera and which presented no reactivity to the negative sera were subsequently sequenced and compared with various databases of sequences currently available (Non-Redundant Genbank CDS, Non-Redundant Database of Genbank Est Division, Non-Redundant Genbank+EMBL+DDBJ+PDB Sequences).
- The sequences obtained can be classified in four groups:
-
- sequences that code for known T. gondii antigen fragments;
- sequences that code for known proteins which, however, are not known to be involved in the human antibody response;
- sequences that code for unknown proteins (e.g. EST);
- new sequences, not yet figuring in the databases.
- The following table 2 gives, by way of examples, the sequences of some of the clones selected:
TABLE 2 Name of clone Sequence Identification Classification Tx-4.11 AGTGGAGGGACAGGGC GRA 1 Dense granul 
(SEQ ID No 17) AGGGATTAGGAATCGG known protein AGAATCTGTAGATTTG T. gondii GAGATGATGGGGAACA antigen CGTATCGTGTGGAGAG ACCCACAGGCAACCCG GACTTGCTCAAGATCG CCATTAAAGCTTCAGA TGGATCGTACAGCGAA GTCGGCAATGTTAACG TGGAGGAGGTGATTGA TACTATGAAAAGCATG CAGAGGGACGAGGACA TTTCCTTCGTGCGTTG AACAAAGGCGAAACAG TAGAGGAAGCGATCGA AGACGTGGCTCAAGCA GAAGGGCTTAATTCGG AGCAAACCCTGCAACT GGAAGATGCAGTGAGC GCGGTGGCGTCTGTTG TTCAAGACGAG TxM-17.2 TACTCTTCACCACGAA GRA2 Dense granul (SEQ ID No 18) TAGTTGTTTTGATTAG known protein ATATTGCTTCTTCTCC T. gondii ACATATCGCCTCACAA antigen TGTTCGCCGTAAAACA TTGTTTGCTGGTTGTT GCCGTTGGCGCCCTGG TCAACGTCTCGGTGAG GGCTGCCGAGTTTTCC GGAGTTGATTAACCAG GGACCT Tx.15.11 GCTGCCTTGGGAGGCC GRA 3 Dense granul (SEQ ID No 19) TTGCGGCGGATCAGCC protein- TGAAAATCATCAGGCT unknown CTTGCAGAACCAGTTA as antigen i CGGGTGTGGGGGAAGC human AGGAGTGTCCCCCGTC response AACGAAGCTGGTGAGT CATACAGTTCTGCAAC TTCGGGTGTCCAAGAA GCTACCGCCCCAGGTG CAGTGCTCCTGGACGC AATCGATGCCGAGTCG GATAAGGTGGACAATC AGGCGGAGGGAGGTGA GCGTATGAAGAAGGTC GAAGAGGAGTTGTCGT TATTGAGGCGGGAATT ATATGATCGCACAGAT CGCCCTGGT Tx-1.11 CAGTTCGCTACCGCGG GRA 7 Dense granul (SEQ ID No 20) CCACCGCGTCAGATGA known protein CGAACTGATGAGTCGA T. gondii ATCCGAAATTCTGACT antigen TTTTCGATGGTCAAGC ACCCGTTGACAGTCTC AGACCGACGAACGCCG GTGTCGACTCGAAAGG GACCGACGATCACCTC ACCACCAGCATGGATA AGGCATCTGTAGAGAG TCAGCTTCCGAGAAGA GAGCCATTGGAGACGG AGCCAGATGAACAAGA AGAAGTTCAT Tx-8.0 GAGAACCCGGTGAGAC GRA8 Dense granul (SEQ ID No 21) CGCCTCCTCCCGGTTT known protein CCATCCAAGCGTTATT T. gondii CCCAATCCCCCGTACC antigen CGCTGGGCACTCCAGC GGGCATGCCACAGCCA GAGGTTCC Tx-1.16 AGGAGGACTGGATGTC MIC 3 Microneme (SEQ ID No 22) ATGCCTTCAGGGAGAA protein- CTGCAGCCCTGGTAGA unknown a TGTATTGATGACGCCT antigen i CGCATGAGAATGGCTA human CACCTGCGAGTGCCCC response ACAGGGTACTCACGTG AGGTGACTTCCAAGGC GGAGGAGTCGTGTGTG GAAGGAGTCGAAGTCA CGCTGGCTGAGAAATG CGAGAAGGAATTCGGC ATCAGCGCGTCATCCT GCAAATGCGAT Tx-9.18 GCACCCACTCAATCTG MIC 5 Microneme (SEQ ID No 23) AAATGAAAGAATTCCA known protein AGAGGAAATCAAAGAA T. gondii GGGGTGGAGGAAACAA antigen AGCATGAAGACGATCC TGAGATGACGCGGCTC ATGGTGACCGAGAAGC AGGAGAGCAAAAATTT CAGCAAGATGGCGAAA TCCCAGAGTTTAGCAC GCGAATCGAAGAGCTC GGGGGATCCATTTCGT TTCTAACTGAAACGGG GGTCACAATGATCGAG TTGCCCAAAACTGTCA GTGAACATGACATGGA CCAACTACTCCAC Tx-7.11 GTTATGGCATCGGATC SAG 1 Surface (SEQ ID No 24) CCCCTCTTGTTGCCAA known protein TCAAGTTGTCACCTGC T. gondii CCAGATAAAAAATCGA antigen CAGCCGCGGTCATTCT CACACCGACGGAGAAC CACTTCACTCTCAAGT GCCCTAAAACAGCGCT CACAGAGCCTCCCACT CTTGCGTACTCACCCA ACAGGCAAATCTGCCC AGCGGGTACTACAAGT AGCTGTACATCAAAGG CTGTAACATTGAGCTC CTTGATTCCTGAAGCA GAAGATAGCTGGTGGA CGGGGGATTCTGCTAG TCTCGACACGGCAGGC ATCAAACTCACAGTTC CAATCGAGAAGTTCCC CGTGACAACGCAGACG TTTGTGGTCGGTTGCA TCAAGGGAGACGACGC ACAGAGTTGTATGGTC ACGGTGACAGTACAAG CCAGAGCCTCATCGGT CGTCAATAATGTCGCA AGGTGCTCCTATGGTG CGGACAGC Tx-4.18 CCATCGGTCGTCAATA SAG 1 Surface (SEQ ID No 25) ATGTCGCAAGGTGCTC known protein CTACGGTGCAGACAGC T. gondii ACTCTTGGTCCTGTCA antigen AGTTGTCTGCGGAAGG ACCCACTACAATGACC CTCGTGTGCGGGAAAG ATGGAGTCAAAGTTCC TCAAGACAACAATCAG TACTGTTCCGGGACGA CGCTGACTGGTTGCAA CGAGAAATCGTTCAAA GATATTTTGCCAAAAT TAACTGAGAACCCGTG GCAGGGTAACGCTTCG AGTGATAAGGGTGCCA CGCTAACGATCAAGAA GGAAGCATTTCCAGCC GAGTCAAAAAGCGTCA TTATTGGATGCACAGG GGGATCGCCTGAGAAG CATCACTGTACCGTGA AACTGGAGTTTGCCGG GGCTGCAGGGTCAGCA AAATCGGCT - The clone Tx-4.11 constitutes a fragment of the antigen GRA1 (Cesbron-Delauw et al., 1989, Proc. Natl. Acad. Sci. USA 86:7537-7541) but has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 26) SGGTGQGLGIGESVDLEMMGNTYRVERPTGNPDLLKIAIKASDGSYSEVGNVNVEEVIDTMKSMQRDEDIFLR ALNKGETVEEAIEDVAQAEGLNSEQTLQLEDAVSAVASVVQDE and its use as a fragment containing an epitope is covered by the present invention.
- The clone TxM-17.2 constitutes a fragment of the antigen GRA2 (Prince et al., 1989, Mol. Biochem. Parasitol., 34: 3-14) but has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 27) YSSPRIVVLIRYCFFSTYRLTMFAVKHCLLVVAVGALVNVSVRAAEFSGVVNQGP and its use a fragment containing an epitope is covered by the present invention.
- The clone Tx-15.11 constitutes a fragment of the gene GRA3 (Bermudes et al., 1994, Mol. Biochem. Parasitol., 68: 247-257) and has never been identified as an antigen in the human antibody response. Said clone has the amino acid sequence (SEQ ID No 28) AALGGLAADQPENHQALAEPVTGVGEAGVSPVNEAGESYSSATSG VQEATAPGAVLLDAIDAESDKVDNQAEGGERMKKVEEELSLLRRE LYDRTDRPG and its use as a fragment containing an epitope is covered by the present invention.
- The clone Tx-1.11 constitutes a fragment of the antigen GRA7 (Bonhomme et al., 1998, J. Histochem. Cytochem. 46, 1411-1421) and has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 29) FATAATASDDELMSRIRNSDFFDGQAPVDSLRPTNAGVDSKGTDDHLTTSMDKASVESQLPRREPLETEPDEQEEVHF and its use as a fragment containing an epitope is covered by the present invention.
- The clone Tx-8.0 constitutes a fragment of the antigen GRA8 (Kimberly et al., 2000, Mol. Biochem. Parasitol., 105: 25-37) and has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 30) ENPVRPPPPGFHPSVIPNPPYPLGTPAGMPQPEVP and its use as a fragment containing an epitope is covered by the present invention.
- The clone Tx-1.16 constitutes a fragment of the gene MIC3 (Garcia-Réguet et al., 2000, Cellular Microbiol., 2: 353-364) and has never been identified as an antigen in the human antibody response. Said clone has the amino acid sequence (SEQ ID No 31) RRTGCHAFRENCSPGRCIDDASHENGYTCECPTGYSREVTSKAEESCVEGVEVTLAEKCEKE FGISASSCKCD and its use as a fragment containing an epitope is covered by the present invention.
- The clone Tx-9.18 constitutes a fragment of the antigen MIC5 (Brydges et al., 2000, Mol. Biochem. Parasitol., 111: 51-66) but has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 32) APTQSEMKEFQEEIKEGVEETKHEDDPEMTRLMVTEKQESKNFSKMAKSQSFSTRIEELGGSISFLTETGVTMIELPKTVSEHDMDQLL H and its use as a fragment containing an epitope is covered by the present invention.
- The clone Tx-7.11 constitutes a fragment of the antigen SAG1 (Burg et al., 1988, J. Immunol., 141:3584-3591) but has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 33) VMASDPPLVANQVVTCPDKKSTAAVILTPTENHFTLKCPKTALTEPPTLAYSPNR QICPAGTTSSCTSKAVTLSSLIPEAEDSWWTGDSASLDTAGIKLTVPI EKFPVTTQTFVVGCIKGDDAQSCMVTVTVQARASSVVNNVARCSYG ADS and its use a fragment containing an epitope is covered by the present invention.
- The clone Tx-4.18 constitutes a fragment of the antigen SAG1 (Burg et al., 1988, J. Immunol., 141:3584-3591) but has never been identified as an “antigen fragment” of the protein in the human humoral response. Said clone has the amino acid sequence (SEQ ID No 34) PSVVNNVARCSYGADSTLGPVKLSAEGPTTMTLVCGKDGVKVPQDNNQYCSGTT LTGCNEKSFKDILPKLTENPWQGNASSDKGATLTIKEAFPAESKS VIIGCTGGSPEKHHCTVLLEFAGAAGSAKSA and its use as a fragment containing an epitope is covered by the present invention.
- Expression of cDNA Fragments Selected from the Library as Fusion Products with GST
- The plasmid pGEX-SN was constructed by cloning the DNA fragment deriving from the hybridisation of the synthetic oligo-
nucleotides K108 5′-GATCCTTACTAGTTTTAGTAGCGGCCGCGGG-3′ (SEQ ID No 35) andK109 5′-AATTCCCGCGGCCGCTACTAAAACTAGTAAG-3′ (SEQ ID No 36) in the BamHI and EcoRI sites of plasmid pGEX-3X (Smith and Johnson, 1988, Gene, 67, 31-40). - The phage clones for which specific reactivity with sera of patients testing positive for Toxoplasma gondii was demonstrated, were amplified and then analysed with a substantial panel of positive and negative sera. After this ELISA study, DNA inserts of clones that showed multiple reactivity with Toxoplasma gondii-positive sera and presented no reactivity with the negative sera were cloned as fusion products with the protein Glutathione Sulphur Transferase (GST) and expressed in the cytoplasma of bacterial cells, for the purposes of determining their specificity and selectivity. To produce the fusion proteins each clone was amplified from a single phage plaque by PCR, using the following oligonucleotides:
K47 5′-GGGCACTCGACCGGAATTATCG-3′ (SEQ ID No 37) andK85 5′-GGGTAAAGGTTTCTTTGCTCG-3′ (SEQ ID No 38). The resulting fragment was then purified by means of the “Qiagen Purification Kit” (Qiagen, CA, USA), digested with the restriction enzymes SpeI and NotI and cloned in the vector pGEX-SN to generate the fusion with GST. The corresponding recombinant proteins were then expressed in E. coli and purified by affinity using Glutathione-Sepharose resin (Amersham Pharmacia Biotech, Sweden) and following standard protocols (Sambrook et al., 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). - The following table 3, by way of examples, presents the reactivity with negative and positive sera of a number of the clones selected, assayed in the form of fusion proteins:
TABLE 3 Reactivity of GST fusion Reactivity of GST fusion protein Name of protein with positive sera with negative sera clone (pos./total neg.) (neg./total neg.) Tx-4.11 32/40 1/28 Tx-15.11 22/40 0/28 Tx-1.11 27/40 0/28 Tx-8.0 13/40 0/28 Tx-1.16 31/40 0/28 Tx-9.18 3/40 1/28 Tx-7.11 39/40 3/28 Tx-4.18 21/40 1/28
IgG Avidity for Determining the Time of Infection - Measurement of the binding force between immunoglobulin G (IgG) and the T. gondii-specific antigens (IgG avidity) is a diagnostic method used to establish the time of infection: IgG avidity is lower during the acute phase of the infection and then tends to increase in the course of time (Hedman et al. 1989 J. Infect. Dis. 159, 736-740). Evaluation of IgG avidity is based on an enzyme-linked immunosorbent assay (ELISA) in which the immunoglobulins are “detached” from the antigen by washing with a urea denaturing solution. A mathematical calculation based on the reactivity before and after the denaturing washing makes it possible to estimate serum IgG avidity (Jenum et al., 1997. J. Clin. Microbiol. 35, 1972-1977). To evaluate the antigenic properties of the protein fragments described in the present invention, an IgG avidity test based on recombinant antigen fragments was developed and the results obtained were compared with the assay performed with a commercial kit (Toxo-IgG avidity kit, bioMeriéux, France) that employs the whole parasite extract as antigen.
- For the avidity analysis 27 sera coming from women who contracted primary Toxoplasmosis during pregnancy and collected at different times after infection were used. The infection was diagnosed by seroconversion during gestation, taking into consideration last negative and first positive samples. For each sample the specific IgG and IgM levels for T. gondii and the IgG avidity were determined by means of the use of commercial kits (LDBIO Diagnostic, France; bioMeriéux, France). Multi-well plates (Nunc, Denmark) were incubated overnight at 4° C. with a solution of NaHCO3 50 mM, pH 9.6 containing the antigen fragments expressed as GST fusion proteins at a final concentration of 5 μg/ml. The plates were blocked with 200 μl of blocking solution (5% skimmed milk powder in PBS, 0.05% Tween-20) and then washed 5 times with washing buffer (PBS, 0.05% tween-20). Serial dilutions of serum (1:50, 1:200, 1:800, 1:3200) in 100 μl of blocking solution were incubated on plates for 60 minutes at 37° C. The plates were then incubated with a denaturing solution of urea 6M in PBS/0.02% Tween-20 for 30 minutes at 37° C. In parallel, for every sample, the same dilutions of serum were effected and the wells concerned were incubated with normal washing buffer. 100 μl of blocking solution containing human anti-IgG antibodies conjugated with the enzyme alkaline phosphatase (diluted 1:10000) were added to the plates. After 30 minutes' incubation at 37° C. the plates were washed and the enzyme activity was determined with 100 μl of development solution (10% diethanolamine pH 9.8, 0.5 mM MgCl2, 0.05% NaN3) containing the reaction substrate p-nitrophenylphosphate (Sigma-Aldrich, USA). The enzyme activity was measured at optical densities of 405 nm and 620 nm by means of an automatic ELISA OD reader (Multiskan Labsystem, Finland) and the avidity calculation was done according to the mathematical analysis described in the literature (Jenum et al., 1997. J. Clin. Microbiol. 35, 1972-1977).
- The following table 4 gives, by way of examples, the avidity of the human sera for a number of the antigen fragments selected.
- The values should be interpreted as follows (commercial kit criterion):
TABLE 4 Time from Infection Commercial kit Clones-GST Serum (months) bioMerleux tx-15.11 tx-1.11 tx-8.0 tx-4.18 tx-7.11 tx-1.16 T1 1 7.8% 20.0% 6.9% 12.0% — — 24.0% T2 1 5.7% 7.9% 2.3% 10.0% 9.8% 7.9% 2.7% T3 1-2 2.5% 5.4% 6.3% 9.5% 8.7% 11.5% 1.0% T4 1-2 8.1% 4.5% 9.0% 4.0% 10.3% 38.4% 9.5% T5 1-2 4.5% 2.4% 4.0% 9.3% 7.7% 6.7% 11.0% T6 1-2 2.6% 10.0% 4.7% 2.0% 10.0% 7.1% 12.4% T7 1-2 11.6% 9.1% 13.0% 8.0% 15.6% 4.2% 26.0% T8 1-2 6% 4.2% 8.7% 1.7% 7.5% 19.3% 26.2% T9 2-3 4.9% 17.0% 5.5% 3.0% 9.8% 4.8% 21.0% T10 2-3 13.7% 27.0% 30.8% 14.5% 28.1% 4.8% 52.0% T11 2-3 66.1% 41.0% 37.6% 15.7% 42.8% 59.0% 72.0% T12 3-4 16.2% 29.0% 25.1% 13.9% 28.7% 8.6% 56.0% T13 4-5 42.7% 20.1% 59.0% — — 28.6% 89.0% T14 4-5 59.5% 22.0% 32.8% 67.5% 50.9% 75.0% 79.5% T15 5-6 14.7% 25.0% 9.5% 14.6% 19.2% 8.3% 59.0% T16 6 55.1% 35.0% 75.8% 70.0% — 63.5% 79.2% T17 6 15.6% — — — 26.6% 10.2% 45.5% T18 6-7 45.8% 64.0% 59.1% — 46.1% 50.7% 69.0% T19 6-7 25.7% 29.4% 23.0% 30.0% 24.6% 55.6% 62.3% T20 7-8 43.6% 44.0% 48.0% — 63.9% 47.9% 90.0% T21 7-8 52.2% 22.0% 31.0% 16.4% 49.7% 48.2% 69.0% T22 7-8 26.2% 2.5% — 9.0% — — 36.0% T23 8 26.2% 47.3% 47.2% — — 21.0% 42.6% T24 8 22.8% 26.5% 22.4% 82.8% — 16.7% 40.5% T25 10 28.6% 46.0% 52.4% — — 23.2% 37.5% T26 24 25.6% 62.0% 35.3% — — — 73.8% T27 38 41.8% 25.0% 34.1% 55.0% 35.2% 43.8% 58.0% - Using the vector λKM4 of Example 1, a library of DNA fragments of known Toxoplasma gondii genes was constructed.
- Cells of Toxoplasma gondii (106 parasites, strain ME49) were grown in vitro in monkey kidney cells (“VERO” African green monkey cells) using DMEM culture medium containing 10% foetal bovine serum, 2 mM glutamine and 0.05 mg/ml gentamicin (Gibco BRL, Canada). To have both forms of the parasite (tachyzoites and bradyzoites) present in the cell cultures, an experimental protocol was used based on the change in pH of the culture medium (Soete et al., 1994, Experimental Parasitology, 78, 361-370). The parasites were collected after complete lysis of the host cells and purified by filtration (filter porosity 3 μm) followed by centrifuging. 2 μg of mRNA were isolated from 5×106 parasites using the “QuickPrep Micro mRNA Purification Kit” (Amersham Pharmacia Biotech, Sweden) and following the manufacturer's instructions. cDNA was synthesised from 200 ng of poly(A)+ RNA using the “SMART cDNA Library Construction Kit” (Clontech, CA, USA) and following the manufacturer's instructions. Genomic DNA was purified from the remaining 5×106 cells using standard procedures (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY) and stored at −20° C.
- For the construction of the expression/exposure library the following genes, expressed only in the bradyzoite stage, were amplified by means of PCR with specific oligonucleotides:
- 1—SAG2D (Lekutis et al., 2000, Experimental Parasitology, 96, 89-96) was obtained from genomic DNA using the
oligonucleotides 5′-ATGGCGGCTGCACACTCG-3′ (SEQ ID No 39) and 5′-GAACATATTCCCTGTCACCAATG-3′ (SEQ ID No 40); - 2—SAG4 (Odberg-Ferragut et al., 1996, Molecular and Biochemical Parasitology, 82, 237-244) was obtained from genomic DNA using the
oligonucleotides 5′-ATGACGAAAAATAAAATTCTTCTC-3′ (SEQ ID No 41) and 5′-CATTGATATCAACACAAAGGCC-3′ (SEQ ID No 42) - 3—BSR4 (Manger et al., 1998, Infection and Immunity, 66, 2237-2244) was obtained from genomic DNA using the
oligonucleotides 5′-ATGGTGATGATGGGCAGCATG-3′ (SEQ ID No 43) and 5′-CGGCGGCCGCGCTAGAGG-3′ (SEQ ID No 44); - 4—MAG1 (Parmley et al., 1994, Molecular and Biochemical Parasitology, 66, 283-296) was obtained from genomic DNA using the
oligonucleotides 5′-CGTTGGATCCTTGGATTGAGCCAAAGGGTGCCAG-3′ (SEQ ID No 45) and 5′-CCCAGAATTCTCAAGCTGCCTGTTCCGCTAAGATCTG-3′ (SEQ ID No 46); - 5—LDH2 (Yang and Parmley, 1997, Gene, 184, 1-12) was obtained from cDNA using the
oligonucleotides 5′-ATGACGGGTACCGTTAGCAG-3′ (SEQ ID No 47) and 5′-ACCCAGCGCCGCTAAACTC-3′ (SEQ ID No 48); - 6—ENO1 (Dzierszinski et al., 2001, Journal of Molecular Biology, 309, 1017-1027) was obtained from genomic DNA using the
oligonucleotides 5′-ATGGTGGTTATCAAGGACATCG-3′ (SEQ ID No 49) and 5′-TTTTGGGTGTCGAAAGCTCTC-3′ (SEQ ID No 50); - 7—BAG1 (Bohne et al., 1995, Molecular Microbiology, 16, 1221-1230) was obtained from cDNA using the
oligonucleotides 5′-ATGGCGCCGTCAGCATCG-3′ (SEQ ID No 51) and 5′-CTTCACGCTGATTTGTTGCTTTG-3′ (SEQ ID No 52); - 8—p-ATPase (Holpert et al., 2001, Molecular and Biochemical Parasitology, 112, 293-296) was obtained from genomic DNA using the
oligonucleotides 5′-ATGGACGAAGCGAGCAGAAGG-3′ (SEQ ID No 53) and 5′-ACGCGTGATCGAAGGAACCG-3′ (SEQ ID No 54). - 10 μg of DNA deriving from a mixture of the amplification products of the above-mentioned genes were fragmented randomly using 0.5 ng of the endonuclease DNaseI (Sigma-Aldrich, USA). The mixture of DNA and DNaseI was incubated for 20 minutes at 15° C. and the DNA fragments were purified by means of the “QIAquick PCR Purification Kit” (Qiagen, CA, USA), following the manufacturer's instructions. The 3 μg ends of the cDNA fragments were “flattened” by incubating the DNA with 9 units of the enzyme T4 DNA polymerase (New England Biolabs, MA, USA) for 60 minutes at 15° C. The fragments were then purified by means of extraction in phenol/chloroform and subsequent precipitation in ethanol. 500 ng of the resulting DNA were bound with a 20-fold molar excess of “synthetic adaptors” for the purposes of adding the restriction sites SpeI and NotI to the ends of the fragments. Six adaptors were used, obtained by hybridisation of the following pairs of oligonucleotides:
K185 5′-CTAGTCGTGCTGGCCAGC-3′ (SEQ ID No 5) andK186 5′-GCTGGCCAGCACGA-3′ (SEQ ID No 6);K187 5′-CTAGTCGTGCTGGCCA GCT-3′ (SEQ ID No 7) andK188 5′-AGCTGGCCAGCACGA-3′ (SEQ ID No 8);K189 5′-CTAGTCGT GCTGGCCAGCTG-3′ (SEQ ID No 9) andK190 5′-CAGCTGGCCAGCACGA-3′ (SEQ ID No 10);K191 5′-TCTGGTGGCGGTAGC-3′ (SEQ ID No 11) andK192 5′-GGCCGCTACCGCCACCAGA-3′ (SEQ ID No 12);K193 5′-TTCTGGTGGCGGTAGC-3′ (SEQ ID No 13) andK194 5′-GGCCGCTACCGCCACCAGAA-3′ (SEQ ID No 14);K195 5′-TTTCTGGTGGCGGTAGC-3′ SEQ ID No 15) andK196 5′-GGCCGCTACCGCCACCAGAAA-3′ (SEQ ID No 16). The excess of unligated adaptors was removed from the ligation mixture by electropheresis on 2% agarose gel and the cDNA fragments with molecular weights ranging from 250 bp to 1000 bp were excised from the gel and purified by means of the “Qiaquick gel extraction kit” (Qiagen, CA, USA) following the manufacturer's instructions. The vector λKM4 was digested with SpeI/NotI and for the construction of the library 6 ligation mixtures were performed, each containing 0.4 μg of vector and approximately 7 ng of insert. After overnight incubation at 4° C. the ligation mixtures were packaged in vitro with the “Ready-To-Go lambda packaging kit” (Amersham Pharmacia Biotech, Sweden) and plated for infection of BB4 cells (bacterial cells of E. coli strain BB4; Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY). After overnight incubation at 37° C. the phage was eluted from the plates with SM buffer (Sambrook et al., 1989, Molecular Cloning: a laboratory manual, Cold Spring Harbor Laboratory Press, NY), purified, concentrated and stored at −80° C. in SM buffer containing 7% dimethylsulphoxide. The complexity of the library calculated as the number of total independent clones with inserts was 106 clones. - Affinity selection, phage-ELISA, immunoscreening and phage clones preparation were performed exactly as described in Example 1
- The following table 5 gives, by way of examples, the reactivity of a number of the recombinant bacteriophages selected.
TABLE 5 Reactivity of phage clone with Reactivity of phage positive sera (positive/total clone with negative sera Name of clone positive) (negative/total negative) TxB-c121.2 10/20 1/10 TxB-c126.3 12/20 0/10 TxB-44.3 10/20 0/10 TxB-7.1 8/20 0/10 TxB-9.1 1/20 1/10 TxB-12.1 5/20 0/10
Characterisation of Positive Clones - The clones which showed multiple reactivity with the Toxoplasma gondii positive sera and which presented no reactivity with the negative sera were subsequently sequenced and compared with the sequences of the genes used to construct the library
- The following table 6 gives, by way of examples, the sequences of some of the clones selected:
TABLE 6 Name of clone Sequence TxB.26.3 GGATTGAGCCAAAGGGTGCCAGAGCTACCAGAAGT (SEQ ID No 55) GGAGCCCTTTGATGAAGTAGGCACGGGAGCTCGAC GGTCCGGGTCCATTGCGACCCTTCTTCCACAAGAC GCTGTTTTATATGAGAACTCAGAGGACGTTGCCGT TCCGAGTGATTCAGCATCGACCCCGTCATACTTTC ATGTGGAATCTCCAAGTGCTAGTGTGGAAGCCGCG ACTGGCGCTGTGGGAGAGGTGGTGCCGGACTGTGA AGAACAACAGGAACAGGGTGACACGACGTTATCCG ATCACGATTTCCATTCA TxB-c17.1 TCTTCAGAAAGATGACGTAACCATAGAAGTCGACAA (SEQ ID No 56) CGGAGCCATCGTTATCAAAGGAGAGAAGACCTCGAA AGAAGCGGAGAAAGTGGACGATGGCAAAACAAAGAA CATTTTGACTGAGCGAGTGTCCGGTTATTTTGCGCG CCGGTTCCAGCTCCCGAGTAATTACAAGCCCGACGG AATCAGTGCGGCAATGGACAACGGCGTTCTACGTGT CACGATCAAGGTCGAGGATTCAGGGGGCGCAAAGCA ACAAATCAGCGTG - The clone TxB-cl26.3 constitutes a fragment of the gene MAG1, a 65 kDa protein of the matrix and wall of T. gondii cysts (Parmley et al., 1994, Molecular and Biochemical Parasitology, 66, 283-296), the protein product of which has never been identified as an “antigen fragment” in the human humoral response. Said clone has the amino acid sequence GLSQRVPELPEVEPFDEVGTGARRSGSIATLLPQDAVLYENSEDVAVPSDSASTPSYFHVESPSASVEAATGAVGEVVPDCEE QQEQGDTTLSDHDFH (SEQ ID No 57) and its use as a fragment containing an epitope is covered by the present invention.
- The clone TxB-cl7.1 constitutes a fragment of the gene BAG1, a 30 kDa protein of the heat shock protein family of T. gondii (Bohne et al., 1995, Molecular Microbiology, 16, 1221-1230), the protein product of which has never been identified as an “antigen fragment” in the human humoral response. Said clone has the amino acid sequence LNPIDDMLFETALTANEMMEDITWRPRVDVEFDSKKKEMIILADLP GLQKDDVTIEVDNGAIVIKGEKTSKEAEKVDDGKTKNILTERVSGY FARRFQLPSNYIDGISAAMDNGVLRVTIKVEDSGGAKQQISV (SEQ ID No 58) and its use as a fragment containing an epitope is covered by the present invention.
- Expression of DNA Fragments Selected from the Library as fusion Products with GST
- The phage clones for which specific reactivity with sera of patients testing positive for Toxoplasma gondii was demonstrated, were amplified and then analysed with a substantial panel of positive and negative sera. After this ELISA study, the clones that showed multiple reactivity with Toxoplasma gondii-positive sera and presented no reactivity with the negative sera were cloned as fusion products with the protein Glutathione Sulphur Transferase (GST) and expressed in bacterial cells, for the purposes of determining their specificity and selectivity. To produce the fusion proteins each clone was amplified from a single phage plaque by PCR, using the following oligonucleotides:
K47 5′-GGGCACTCGACCGGAATTATCG-3′ (SEQ ID No 37) andK85 5′-GGGTAAAGGTTTCTTTGCTCG-3′ (SEQ ID No 38). The resulting fragment was then purified by means of the “Qiagen Purification Kit” (Qiagen, CA, USA), digested with the restriction enzymes SpeI and NotI and cloned in the vector pGEX-SN to generate the fusion with GST. The corresponding recombinant proteins were then expressed in E. coli and purified by affinity using Glutathione-Sepharose resin (Amersham Pharmacia Biotech, Sweden) and following standard protocols (Sambrook et al., 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). - The following table 7, by way of examples, presents the reactivity with negative and positive sera of a number of the clones selected, assayed in the form of fusion proteins:
TABLE 7 Reactivity of GST fusion Reactivity of GST fusion protein with positive portein with negative Name of clone sera (pos./total neg.) sera (neg./totale neg.) TxB-c126.3 30/34 0/32 TxB-c17.1 17/34 0/32 - By using the same strategy described in Example 2, a gene collection of DNA encoding for protein products of the Toxoplasma gondii microneme family was used to construct a “microneme-display library”.
- For the construction of the microneme-library the following genes were amplified by means of PCR with specific oligonucleotides:
- 1—MIC2 (Wan et al, 1997, Mol. Biochem. Parasitol. 84: 203-214) was obtained from single strand cDNA using the
oligonucleotides 5′-ATGAGACTCCAACCGAGGCC-3′ (SEQ ID No 69) and 5′-CTGCCTGACTCTTTCTTGGACTG-3′ (SEQ ID No 70); - 2—M2AP (Rabenau et al., 2001, Mol. Microbiol. 41: 537-547) was obtained from single strand cDNA using the
oligonucleotides 5′-GGAAAGTTGGAAATCCGGCGGC-3′ (SEQ ID No 71) and 5′-CGCCTCATCGTCACTCGGC-3′ (SEQ ID No 72) - 3—MIC4 (Brecht et al., 2001, J. Biol. Chem. 276:4119-412) was obtained from single strand cDNA using the
oligonucleotides 5′-ATGAGAGCGTCGCTCCCGG-3′ (SEQ ID No 73) and 5′-GTGTCTTTCGCTTCAAGCACCTG-3′ (SEQ ID No 74); - 4—AMA1 (Hehl et al., 2000, Infect. Immun. 68:7078-7086) was obtained from single strand cDNA using the
oligonucleotides 5′-ATGGGGCTCGTGGGCGTAC-3′ (SEQ ID No 75) and 5′-GATCAACGCAGTGTTAGAGCCAC-3′ (SEQ ID No 76); - 10 μg of DNA deriving from a mixture of the amplification products of the above-mentioned genes were fragmented randomly using 0.5 ng of the endonuclease DNaseI (Sigma-Aldrich, USA). The mixture of DNA and DNaseI was incubated for 20 minutes at 15° C. and the DNA fragments were purified by means of the “QIAquick PCR Purification Kit” (Qiagen, CA, USA), following the manufacturer's instructions. Consequent steps for the construction of the microneme-library, and for the affinity selection were performed by following the procedure described in Example 2.
- Selection of the Microneme-Library with Sera of Infants Who Were Infected by T. gondii During Pregnancy
- To identify the antigenic domains of the T. gondii microneme proteins an affinity selection procedure was used consisting of two “panning” cycles with four sera collected from infants who were congenitally infected by the parasite, followed by an immunological screening procedure carried out with the same sera. The library was selected with sera T1, T2, T3, T4, generating, after a single selection cycle, the corresponding mixtures p1I, p2I, p3I and p4I. Each mixture was then subjected to a second affinity selection cycle with the same serum, giving rise to a second series of mixtures (called p1IIp2II, p3II and p4II). Various positive clones were identified by means of immunoplate screening per plaque of reactive mixtures.
- Phage-Elisa, immunoscreening, and the preparation of phage clones were subsequently performed exactly as described in Examples 1 and 2.
- The following table 8 gives, by way of examples, the reactivity of a number of the recombinant bacteriophages selected.
TABLE 8 Reactivity of phage Reactivity of phage clone with clone with positive sera negative sera (negative/total Name of clone (positive/total positive) negative) Tx-2.a 13/16 0/10 Tx-1.b 11/16 0/10 Tx-11.b 12/16 0/10 Tx-13.b 9/16 0/10 Tx-15.b 9/16 0/10
Characterisation of Positive Clones - The following table 9 gives the sequences of the clones selected:
TABLE 9 Name of the clone Sequence Identification Classification Tx-2.a CCCCAGGATGCCATTT MIC2 Microneme (SEQ ID No 59) GCTCGGATTGGTCCGC protein ATGGAGCCCCTGCAGT unknown as GTATCCTGCGGTGACG antigen in GAAGCCAAATCAGGAC human response GCGAACTGAGGTTTCT GCTCCGCAACCTGGAA CACCAACATGTCCGGA CTGCCCTGCGCCCATG GGAAGGACTTGCGTGG AACAAGGCGGACTTGA AGAAATCCGTGAATGC AGTGCGGGGGTATGTG CTGTTGACGCTGGATG TGGCGTCTGGGTT Tx-1.b CCGTGTCCAATTAATG MIC2 Microneme (SEQ ID No 60) CAACTTGCGGTCAGTT protein TGAAGAATGGAGTACA unknown as TGCTCGGTCTCATGTG antigen in GTGGTGGACTGAAAAC human response GAGGTCGAGGAACCCT TGGAATGAAGACCAAC AACATGGAGGACTATC CTGCGAGCAGCAGCAT CCTGGTGGGCGGACGG AAACGGTAACTTGCAA TCCTCAAGCGTGTCCT GTGGATGAACGACCGG GGGAGTGGGCAGAGTG GGGGGAATGTAGTGTC ACGTGCGGCGACGGAG TGCGAGAGCGCAGGCG CGGGAAAAGTCTAGTT GAGGCTAAATTCGGCG GACGCACCATTGATCA GCAGAATGAGGCTCTT CCGGAAGACTTAAAAA TCAAAAACGTCGAGTA TGAGCCATGTTCGTAT CCTGCTTGTGGAGCTT CCTGCACGTACGTCTG GAGTGACTGGAACAAG Tx-11.b AACGAACCGGTGGCCC M2AP Microneme (SEQ ID No 61) TAGCTCAGCTCAGCAC protein unknown ATTCCTCGAGCTCGTC as antigen in GAGGTGCCATGTAACT human response CTGTTCATGTTCAGGG GGTGATGACCCCGAAT CAAATGGTCAAAGTGA CTGGTGCAGGATGGGA TAATGGCGTTCTCGAG TTCTATGTCACGAGGC CAACGAAGACAGGCGG GGACACAAGCCGAAGC CATCTTGCGTCGATCA TGTGTTATTCCAAGGA CATTGACGGCGTGCCG TCAGACAAAGCGGGAA AGTGCTTTCTGAAGAA CTTTTCTGGTGAAGAC TCGTCGGAAATAGACG AAAAAGAAGTATCTCT ACCCATCAAGAGCCAC AACGATGCGTTCATGT TCGTTTGTTCTTCAAA TGATGGATCCGCACTC CAGTGTGATGTTTTCG CCCTTGATAACACCAA CTCTAGCGACGGGTGG AAAGTGAATACCGTGG ATCTTGGCGTCAGCGT TAGTCCGGATTTGGCA TTCGGACTCACTGCAG ATGGGGTCAAGGTGAA GAAGTTGTACGCAAGC AGCGGCCTGACAGCGA TCAACGACGACCCTTC CTTGGGGTGCAAGGCT CCTCCCCATTCTCCGC CGGCCGGAGAGGAACC GAGTTTGGCGTCGCCT GAAAACAGCGGGTCTG CAACACCAGGGGAAGA AAGTCCGTCTGAGTCT GAATCT Tx-13.b CTTCGCGGGTACAGGT AMA1 Microneme (SEQ ID No 62) TCGGTGTTTGGAAGAA protein AGGCCGTTGCCTCGAC unknown as TACACTGAATTGACCG antigen in ACACTGTGATAGAACG human response TGTTGAGTCAAAGGCA CAGTGCTGGGTGAAAA CCTTTGAAAACGACGG GGTCGCGAGTGACCAA CCCCATACGTATCCAC TGACGTCGCAAGCATC ATGGAACGATTGGTGG CCTCTCCACCAGAGTG ACCAACCTCACTCAGG TGGCGTTGGGCGTAAT TACGGTTTCTACTACG TGGACACGACTGGAGA GGGCAAGTGTGCACTC TCTGACCAGGTACCCG ACTGCCTGGTGTCGGA TTCTGCCGCCGTGTCG TATACAGCAGCGGGGA GTTTGTCTGAAGAGAC GCCGAATTTCATAATT CCGTCAAATCCCTCTG TTACTCCGCCAACGCG CGAGACGGCACTTCAG TGCACGGCCGACAAGT TCCCCGACTCTTTCGG TGCCTGCGACGTTCAA GCCTGTAAAAGACAGA AGACGTCCTGCGTTGG CGGACAGATTCAAAGT ACTAGCGTCGACTGCA CCGCGGACGAACAAAA TGAATGTGGCTCTAAC ACTGCG Tx15.b AGTGCCAACGTAACAA MIC4 Microneme (SEQ ID No 63) GTTCGGAGCCTGCAAA protein- ACTTGATCTCTCTTGT unknown as GCGCACTCTGACAATA antigen in AGGGATCAAGGGCTCC human response CACAATAGGCGAGCCA GTGCCAGATGTGTCCC TGGAACAATGTGCTGC GCAATGCAAGGCTGTT GATGGCTGCACACATT TCACTTATAATGACGA TTCGAAGATGTGCCAT GTGAAGGAGGGAAAAC CCGATTTATACGATCT CACAGGAGGCAAAACA GCACCGCGCAGTTGCG ATAGATCATGCTTCGA ACAACACGTATCGTAT GAGGGAGCTCCTGACG TGATGACAGCGATGGT CACGAGCCAGTCAGCG GACTGTCAGGCTGCGT GTGCGGCTGACCCGAG CTGCGAGATCTTCACT TATAACGAACACGACC AGAAATGTACTTTCAA AGGAAGGGGGTTTTCT GCGTTTAAGGAACGAG GGGTGTTGGGTGTGAC TTCCGGGCCGAAACAG TTCTGCGATGAAGGCG GTAAATTAACT - The clones Tx-2.a e Tx-1.b represent two distinct fragments of the MIC2 gene (Wan et al, 1997, Mol. Biochem. Parasitol. 84: 203-214) and have never been identified as antigens of the human antibody response. Said clones have respectively the amino acid sequences PQDAICSDWSAWSPCSVSCGDGSQIRTRTEVSAPQPGTPTCPDCPA PMGRTCVEQGGLEEIRECSAGVCAVDAGCGVWV (SEQ ID No 64) and PCPINATCGQFEEWSTCSVSCGGGLKTRSRNPWNEDQQHGGLSCE QQHPGGRTETVTCNPQACPVDERPGEWAEWGECSVTCGDGVRER RRGKSLVEAIFGGRTIDQQNEALPEDLKIKNVEYEPCSYPACGASC TYVWSDWNK (SEQ ID No 65) and their use as fragments containing an epitope is covered by the present invention.
- The clone Tx-11.b represents a distinct fragment of the M2AP gene (Rabenau et al., 2001, Mol. Microbiol. 41: 537-547) and has never been identified as antigen of the human antibody response. Said clone has the amino acid sequence NEPVALAQLSTFLELVEVPCNSVHVQGVMTPNQMVKVTGAGWDNGVLEFYVTRPTKTGGDTSRSHIASIMCYSK DIDGVPSDKAGKCFLKNFSGEDSSEIDEKEVSLPIKSHNDAFMFVC SSNDGSALQCDVFALDNTNSSDGWKVNTVDLGVSVSPDLAFGLTA DGVKVLYASSGLTAINDDPSLGCKAPPHSPPAGEEPSLPSPENS GSATPAEESPSESES (SEQ ID No 66) and its use as fragment containing an epitope is covered by the present invention.
- The clone Tx-13.b represents a fragment of the AMA1 gene (Hehl et al., 2000, Infect. Immun. 68:7078-7086). Said clone has the amino acid sequence LRGYRFGVWKKGRCLDYTELTDTVIERVESKAQCWVKTFENDGVASDQPHTYPLTSQASWNDWWPLHQSDQPHSGGVGRNYG FYYVDTTGEGKCALSDQVPDCLVSDSAAVSYTAAGSLSEETPNFIIP SNPSVTPPTPETALQCTADKFPDSFGACDVQACKRQKTSCVGGQIQ STSVDCTADEQNECGSNTA (SEQ ID No 67) and its use as fragment containing an epitope is covered by the present invention.
- The clone Tx-15.b represents a fragment of the MIC4 gene (Brecht et al., 2001, J. Biol. Chem. 276:4119-4127). Said clone has the amino acid sequence SANVTSSEPAKLDLSCAHSDNKGSRAPTIGEPVPDVSLEQCAAQCKAVDGCTHFTYNDDSKMCHVKEGKPDLYDLTGGKTAPRS CDRSCFEQHVSYEGAPDVMTAIVTSQSADCQAACAADPSCEIFTY NEHDQKCTFKGRGFSAFKERGVLGVTSGPKQFCDEGGKLT (SEQ ID No 68) and its use as fragment containing an epitope is covered by the present invention.
- Expression of DNA Fragments Selected from the Microneme-Library as Fusion Products with GST
- Phage clones isolated from the microneme-library were cloned as fusion products with GST protein and expressed in bacterial cells, for the purposes of determining their specificity and selectivity. The procedure described in Examples 1 and 2 was used to produce the fusion proteins.
- The following table 10, by way of example, presents the reactivity with negative and positive sera of a number of the clones selected, assayed in the form of fusion proteins:
TABLE 10 Reactivity of GST fusion Reactivity of GST fusion protein with positive sera portein with negative sera Name of clone (pos./total neg.) (neg./totale neg.) Tx-2.a 29/30 0/15 Tx-1.b 15/30 0/15 Tx-11.b 23/30 0/15 Tx-13.b 24/30 0/15 Tx-15.b 12/30 0/15 -
Claims (28)
1. Method for the identification of antigen fragments and/or fragments containing epitopes of Toxoplasma gondii proteins, particularly phase-specific antigen fragments, by means of selection of libraries of cDNA or DNA fragments of specific genes of the parasite with sera of subjects who have been infected, using the phage display technique, characterised in that it uses the vector λKM4.
2. Antigen fragments and/or fragments containing epitopes of Toxoplasma gondii proteins obtainable with the method according to claim 1 .
3. Antigenic portions of the fragments according to claim 2 .
4. Antigen fragment and/or fragment containing an epitope according to claim 3 with the following amino acid sequence:
5. Collection of antigen fragments obtainable with the method according to claim 1 .
6. Nucleotide sequence coding for an antigen fragment according to claim 2 .
7. Nucleotide sequence coding for an antigen fragment according to claim 4 selected from the group consisting of:
8. Nucleotide sequences that hybridise with the sequences coding for the sequences according to claim 4 , under stringent hybridisation conditions.
9. Nucleotide sequences that hybridise with the sequences coding for the antigen fragments according to claim 2 under stringent hybridisation conditions.
10. Use of an antigen fragment according to claim 4 as active agents for the diagnosis of Toxoplasma gondii infections.
11. Use according to claim 10 for the diagnosis of the time of infection.
12. Use according to claim 11 , where said time of infection is determined by the IgG avidity assay.
13. Specific ligand for an epitope according to claim 2 .
14. Anti-epitope antibody raised against an epitope according to claim 2 .
15. Ligands for the collection according to claim 5 .
16. Anti-collection antibody raised against a collection according to claim 5 .
17. Use of at least one ligand according to claim 13 for the preparation of means for the diagnosis of Toxoplasma gondii infection.
18. Use of ligands according to claim 15 for the preparation of means for the diagnosis of Toxoplasma gondii infection.
19. Method for the diagnosis of Toxoplasma gondii infection, comprising the selection of sera of subjects affected by or suspected of being affected by said infection with the antigen fragments of claim 1 and/or with at least one ligand of said antigen and/or at least one antibody to the same.
20. Use of antigen fragments according to claim 2 as medicaments.
21. Use of antigen fragments of claim 2 as active agents for the preparation of medicaments for the prevention or treatment of Toxoplasma gondii infections.
22. Use of the sequences according to claim 6 as medicaments.
23. Use of the sequences according to claim 6 for the preparation of medicaments useful for the treatment and prevention of Toxoplasma gondii infections.
24. Diagnostic kit for the diagnosis of Toxoplasma gondii infection, containing at least one antigen fragment according to claim 2 .
25. Kit for the diagnosis of an acute and/or chronic Toxoplasma gondii infection, containing at least one antigen fragment according to claim 4 .
26. Pharmaceutical composition, particularly in the form of a vaccine, containing at least one antigen fragment according to claim 2 .
27. Pharmaceutical composition, particularly in the form of a vaccine, containing at least one sequence according to claim 6 .
28. Composition according to claim 26 suitable for human and/or veterinary use.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/586,694 US20070141076A1 (en) | 2002-03-21 | 2006-10-26 | Antigen fragments for the diagnosis of Toxoplasma gondii |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002RM000159A ITRM20020159A1 (en) | 2002-03-21 | 2002-03-21 | ANTIGENIC FRAGMENTS FOR THE DIAGNOSIS OF TOXOPLASMA INFECTION GONDII METHOD FOR THEIR OBTAINING THEIR USE IN DIAGNOSTIC KITS AND FOR THE |
| ITRM2002A000159 | 2002-03-21 | ||
| ITRM2002A000568 | 2002-11-13 | ||
| ITRM20020568 ITRM20020568A1 (en) | 2002-11-13 | 2002-11-13 | ANTIGENIC FRAGMENTS OF TOXOPLASMA GONDII, METHOD FOR THEIR OBTAINING, THEIR USE IN DIAGNOSTIC KITS AND FOR THE PREPARATION OF VACCINES. |
| PCT/IT2003/000162 WO2003080839A2 (en) | 2002-03-21 | 2003-03-18 | Antigen fragments for the diagnosis of toxoplasma gondii |
| US10/508,622 US7176286B2 (en) | 2002-03-21 | 2003-03-18 | Antigen fragments for the diagnosis of Toxoplasma gondii |
| US11/586,694 US20070141076A1 (en) | 2002-03-21 | 2006-10-26 | Antigen fragments for the diagnosis of Toxoplasma gondii |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/508,622 Division US7176286B2 (en) | 2002-03-21 | 2003-03-18 | Antigen fragments for the diagnosis of Toxoplasma gondii |
| PCT/IT2003/000162 Division WO2003080839A2 (en) | 2002-03-21 | 2003-03-18 | Antigen fragments for the diagnosis of toxoplasma gondii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20070141076A1 true US20070141076A1 (en) | 2007-06-21 |
Family
ID=28456094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/508,622 Expired - Fee Related US7176286B2 (en) | 2002-03-21 | 2003-03-18 | Antigen fragments for the diagnosis of Toxoplasma gondii |
| US11/586,694 Abandoned US20070141076A1 (en) | 2002-03-21 | 2006-10-26 | Antigen fragments for the diagnosis of Toxoplasma gondii |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/508,622 Expired - Fee Related US7176286B2 (en) | 2002-03-21 | 2003-03-18 | Antigen fragments for the diagnosis of Toxoplasma gondii |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7176286B2 (en) |
| EP (1) | EP1485484A2 (en) |
| AU (1) | AU2003219541A1 (en) |
| BR (1) | BR0308620A (en) |
| PL (1) | PL374109A1 (en) |
| WO (1) | WO2003080839A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122795A3 (en) * | 2021-12-23 | 2023-08-31 | The Johns Hopkins University | Treatment and diagnosis of toxoplasma-associated disease |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1856159T1 (en) | 2005-03-08 | 2010-08-31 | Sigma Tau Ind Farmaceuti | Chimeric recombinant antigens of toxoplasma gondii |
| US20100093062A1 (en) * | 2007-03-20 | 2010-04-15 | University Of Maryland Biotechnology Institute | Transfection system for perkinsus species |
| EP2108656A1 (en) | 2008-03-19 | 2009-10-14 | Beninati, Concetta | Antigenic protein fragments of streptococcus pneumoniae |
| CN108265070B (en) * | 2016-12-30 | 2022-07-26 | 中国农业科学院上海兽医研究所 | Specific toxoplasma gondii detection method |
| CN111138553B (en) * | 2020-01-17 | 2020-09-25 | 吉林大学第一医院 | Fusion protein, toxoplasma subunit vaccine and vaccine composition thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022546A (en) * | 1989-12-08 | 2000-02-08 | Dade Behring Marburg Gmbh | Toxoplasma gondii antigens, the preparation thereof and the use thereof |
| US6392014B1 (en) * | 1992-06-15 | 2002-05-21 | Marie-France Cesbron | Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications |
| US6420540B1 (en) * | 1994-10-06 | 2002-07-16 | Akzo Nobel N.V. | Toxoplasma gondii antigens |
| US20020172985A1 (en) * | 1994-07-13 | 2002-11-21 | Eric Jacobs | Cassette for expressing a Toxoplasma gondii P30 protein |
| US20050210535A1 (en) * | 2000-11-09 | 2005-09-22 | University Of Vermont And State Agricultural College | Toxoplasma gondii apical membrane antigen-1 |
-
2003
- 2003-03-18 EP EP03715354A patent/EP1485484A2/en not_active Withdrawn
- 2003-03-18 BR BR0308620-8A patent/BR0308620A/en not_active IP Right Cessation
- 2003-03-18 WO PCT/IT2003/000162 patent/WO2003080839A2/en not_active Application Discontinuation
- 2003-03-18 PL PL03374109A patent/PL374109A1/en unknown
- 2003-03-18 AU AU2003219541A patent/AU2003219541A1/en not_active Abandoned
- 2003-03-18 US US10/508,622 patent/US7176286B2/en not_active Expired - Fee Related
-
2006
- 2006-10-26 US US11/586,694 patent/US20070141076A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022546A (en) * | 1989-12-08 | 2000-02-08 | Dade Behring Marburg Gmbh | Toxoplasma gondii antigens, the preparation thereof and the use thereof |
| US6392014B1 (en) * | 1992-06-15 | 2002-05-21 | Marie-France Cesbron | Cloning of gene encoding the GP28.5 protein of Toxoplasma gondii; peptide fragments of said protein and their applications |
| US20020172985A1 (en) * | 1994-07-13 | 2002-11-21 | Eric Jacobs | Cassette for expressing a Toxoplasma gondii P30 protein |
| US6420540B1 (en) * | 1994-10-06 | 2002-07-16 | Akzo Nobel N.V. | Toxoplasma gondii antigens |
| US20050210535A1 (en) * | 2000-11-09 | 2005-09-22 | University Of Vermont And State Agricultural College | Toxoplasma gondii apical membrane antigen-1 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023122795A3 (en) * | 2021-12-23 | 2023-08-31 | The Johns Hopkins University | Treatment and diagnosis of toxoplasma-associated disease |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003080839A2 (en) | 2003-10-02 |
| WO2003080839A3 (en) | 2004-01-08 |
| BR0308620A (en) | 2005-02-15 |
| US7176286B2 (en) | 2007-02-13 |
| AU2003219541A1 (en) | 2003-10-08 |
| AU2003219541A8 (en) | 2003-10-08 |
| EP1485484A2 (en) | 2004-12-15 |
| PL374109A1 (en) | 2005-09-19 |
| US20050089867A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0690307B1 (en) | Method of determining the presence of an autoimmune antibody | |
| US20090092630A1 (en) | Chimeric recombinant antigens of toxoplasma gondii | |
| Beghetto et al. | Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries | |
| US20070141076A1 (en) | Antigen fragments for the diagnosis of Toxoplasma gondii | |
| JP4792402B2 (en) | Apicomplex's vaccination strain | |
| KR20220009960A (en) | Recombinant Classical Swine Fever Virus | |
| US6855323B2 (en) | Identification of the domain of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) that mediates adhesion to chondroitin sulfate A | |
| US20080107645A1 (en) | Neospora caninum isolate | |
| Flores-Chavez et al. | Polymerase chain reaction detection and serologic follow-up after treatment with benznidazole in Bolivian children infected with a natural mixture of Trypanosoma cruzi I and II | |
| US6403103B1 (en) | Trypanosoma cruzi antigen, gene encoding therefore, and methods of detecting and treating chagas disease | |
| MXPA06006381A (en) | Use of gene ncsag4. | |
| AU2001277390B2 (en) | Neospora caninum isolate. | |
| WO1993011157A1 (en) | MALARIAL VACCINE AND PEPTIDES COMPRISING HUMAN T-CELL EPITOPE OF CIRCUMSPOROZOITE PROTEIN OF $i(P.VIVAX) | |
| Ma | Identification of Babesia microti Diagnostic Antigens Using Phage Display cDNA Library Screening | |
| Smith¹ et al. | Serological Recognition of Toxoplasma gondii Cyst Antigens JE Smith¹, G. McNeil², YW Zhang³, S. Dutton4, G. Biswas-Hughes¹, and P. Appleford¹ | |
| AU2001277390A1 (en) | Neospora caninum isolate. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |